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4ABSTRACT
The incidence and complications of peptic ulcer disease (PUD) have declined during 
the last two decades in Western countries. While the prevalence of Helicobacter 
pylori (H.pylori) infection has declined, the use of non-steroidal anti-inflammatory 
drugs (NSAIDs) has become a more significant risk factor for PUD. In addition, the 
proportion of non-helico-non-NSAID ulcers among PUD patients has increased. 
Other known risk factors for PUD and its complications are previous ulcer, older 
age, smoking and comorbidity. Despite the awareness of risk factors and the use 
of H.pylori infection eradication therapy and proton-pump inhibitors (PPIs), 
mortality associated with PUD has not declined as supposed.
The aims of this thesis were to evaluate time trends in the incidence of PUD 
and its complications, the significance of PUD among patients hospitalised due to 
acute gastrointestinal bleeding (GIB), risk factors for PUD recurrence and mortality, 
and survival of these patients. 
In the retrospective part of the study, register data on patients hospitalised and 
diagnosed with PUD in the capital area of Finland during 2000-2008 was collected 
to analyse incidence rates of PUD and its complications, associated risk factors, 
recurrence of PUD, and mortality associated with PUD. In the prospective part 
of the study, data on patients admitted for acute oesophagogastroduodenoscopy 
(OEGD) during 2012-2014 was collected to analyse the significance of PUD and 
its differential diagnoses in those patients. In addition to endoscopy reports, data 
on smoking, alcohol use, obesity, comorbidity, and medication including over-the-
counter products were collected to analyse risk factors for mortality and survival 
of PUD patients.
The incidence rate of PUD declined from 121/100 000 in 2000-2002, to 79/100 
000 in 2006-2008. The incidence of complications, i.e. bleeding and perforation, 
also declined during the same time. The first-year cumulative incidence of recurrent 
ulcers was 13%. The number of different drugs used, prior to the first ulcer, was 
associated with the recurrence compared to the PUD patients with no drug use. No 
statistically significant difference appeared in the one-year standardised mortality 
ratio (SMR) of PUD patients during 2000-2008. The 30-day all-cause mortality 
was 4%, and the one-year mortality was 12%. The main causes of deaths were 
cardiovascular diseases and malignancies. PUD was regarded as the main cause of 
death for one third of the patients who died within 30 days, but it explained less 
than 15% of mortality within one year. The long-term survival of the PUD patients 
was significantly poorer than that for the age- and gender-matched background 
population. The use of statins prior the hospitalisation for PUD was associated 
5with a significant reduction in the overall mortality, whereas the prior use of PPIs 
did not affect the one-year survival. 
PUD was still the most common source (23%) of bleeding in patients admitted 
for OEDG due to acute bleeding symptoms during the years 2012-2014. The short-
term 30-day mortality among PUD patients was low at 0.7% in this cohort, but 
the one-year mortality was 13%. Of all PUD patients, 35% had major stigmata of 
bleeding (Forrest Ia-IIb ulcers) in OEDG. The use of bleeding-related drugs did not 
differ among the patients with major or minor stigmata of bleeding. Comorbidity 
was associated with decreased survival, whereas stigmata of bleeding, older age, 
smoking or amount of alcohol use did not have an effect on survival. Obesity was 
associated with better survival among PUD patients. 
Of all patients referred for acute OEGD due to acute bleeding symptoms, no 
cause for bleeding was diagnosed in 19% of the patients. In further examinations 
undertaken, the most common finding was diverticular disease of the colon, which 
was considered as the most probable source of bleeding. The source of bleeding 
after further examinations remained unknown in 24% of patients. However, none 
of these patients with negative OEGD for bleeding symptoms died during the 
hospitalisation, and the one-year mortality was 6%, mainly explained by severe 
comorbidity. 
Despite the declining incidence of PUD and its complications among hospitalised 
patients, PUD is still the most common cause for acute upper gastrointestinal 
bleeding leading to hospitalisation. In addition, mortality associated with PUD is 
remarkable with no change in the beginning of the 21st century in Finland.  
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1 INTRODUCTION
Peptic ulcer disease (PUD) has been the most common source of bleeding diagnosed 
among patients admitted to a hospital for acute upper gastrointestinal bleeding 
(GIB). Patients presenting with perforated peptic ulcer (PPU) is another severe 
complication of PUD requiring hospitalisation. 
The incidence of PUD and its complications have declined over the last two 
decades in the Western world. The Helicobacter pylori (H.pylori) infection and 
the use of non-steroidal anti-inflammatory drugs (NSAIDs) are essential factors in 
the pathogenesis and recurrence of PUD. Besides, older age, comorbidity, and the 
concomitant use of certain drugs increases the risk of PUD and its complications. 
Despite the use of eradication therapy for the H.pylori infection and proton-pump 
inhibitors (PPIs), and advanced endoscopic therapy possibilities available during 
recent decades, mortality associated with PUD has not decreased concurrently 
with the incidence.
This thesis includes the retrospective and prospective study part evaluating 
PUD leading to hospitalisation in the beginning of the 21st century in the capital 
area of Finland. The aims of the retrospective register-based part of the study 
were to evaluate time trends in the incidence of PUD and its major complications, 
bleeding and perforation. The risk factors for PUD recurrence and mortality were 
analysed, as well as the causes of death. The survival of hospitalised PUD patients 
was compared with the age- and gender-matched background population. 
In the prospective observational study part, the prevalence of PUD among the 
patients referred for acute oesophagogastroduodenoscopy (OEGD) was evaluated. 
Among the PUD patients possible risk factors including age, gender, living habits, 
comorbidity, medication including over-the-counter products, and bleeding 
stigmata, for the short- and long-term mortality were analysed. The patients 
with acute GIB symptoms with negative OEGD presented nearly one fifth of the 
all prospective cohort patients, and therefore were analysed more particularly 
to evaluate these patients´ characteristics, further examinations undertaken to 
diagnose the non-upper-GI source of bleeding, and the short- and long-term 
mortality of these patients.
11
2 REVIEW OF THE LITERATURE 
2.1 INCIDENCE AND PREVALENCE
The number of patients with asymptomatic PUD is unknown. Many patients with 
uncomplicated PUD are treated empirically without an endoscopically confirmed 
diagnosis, which affects epidemiological studies carried out and explains fluctuation 
in reported results.  According to the systematic review of studies published 1997-
2006, the incidence rate of uncomplicated PUD was 90 (95% CI: 78-104) per 
100 000 for all patients and 71 (61-82) for hospitalised patients (Lin et al. 2011). 
The incidence rate of uncomplicated PUD in a population-based cohort declined 
from 110 to 52 per 100 000 inhabitants per year during 1997-2005 in the UK 
(Cai et al. 2009). 
The incidence of PUD leading to hospitalisation has also declined during recent 
decades (Post et al. 2006, Wang et al. 2010, Lin et al. 2011, Leow et al. 2016), with 
few studies reporting the overall incidence of all uncomplicated and complicated 
PUD requiring hospitalisation varying from 55 to 165 per 100 000 (Table 1). In 
the Netherlands during 1980-2003, the incidence of hospitalisations for PUD 
decreased significantly mainly due to a decrease in the hospitalisation rate for 
patients with uncomplicated PUD (Post et al. 2006). 
Table 1. Incidence rates of both uncomplicated and complicated peptic ulcer disease among patients 
requiring hospitalisation per 100 000 adult inhabitants per year.
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The incidence rate of PUD was higher among men and increased by age 
(Pérez-Aisa et al. 2005, Kang et al. 2006, Lassen et al. 2006, Post et al. 2006, 
Cai et al. 2009, Feinstein et al. 2010). The incidence of duodenal ulcers was 
higher than that of gastric ulcers in Spain (Pérez-Aisa et al. 2005) as also 
seen in other countries (Kang et al. 2006, Post et al. 2006). Contradictory 
results have been reported from the USA, where the hospitalisation rate for 
gastric ulcers was significantly higher (Feinstein et al. 2010), as well as from 
The incidence rate of PUD was higher among men and increased by age (Pérez-
Aisa et al. 2005, Kang et al. 2006, Lassen et al. 2006, Post et al. 2006, Cai et al. 
2009, Feinstein et al. 2010). The incidence of duodenal ulcers was higher than that 
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(Kang et al. 2006, Post et al. 2006). Contradictory results have been reported from 
th  USA, where th  hos italisation rate for gastric ulcers was signific ntly higher 
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(Feinstein et al. 2010), as well as from Denmark with a slightly higher incidence 
of uncomplicated gastric ulcers (Lassen et al. 2006).
The prevalence of endoscopically confirmed PUD was 4.1% in the general adult 
population in Sweden in the Kalixanda cross-sectional study during 1998-2001 (Aro 
et al. 2006). Of these patients, 81% reported PUD-related symptoms, whereas the 
others were asymptomatic. In other population-based studies from Europe and 
the USA, the one-year prevalence of PUD has ranged from 0.1% to 1.5% (Sung et 
al. 2009). However, in a recent study from Asia, the prevalence of asymptomatic 
PUD diagnosed endoscopically in the Taiwanese population was 9.4% (Wang et 
al. 2011). In another study from China, the prevalence of PUD among a randomly 
selected cohort of adults was 17% with most patients (72%) being asymptomatic 
(Li et al. 2010).
2.2 ETIOLOGY AND RISK FACTORS
The H.pylori infection and the use of NSAIDs also covering the use of acetylsalicylic 
acid (ASA) are the two main factors in the aetiology of peptic ulcer disease 
(Yeomans 2011). These are also independent risk factors for PUD complications. 
Other associated risk factors for ulcer formation and its complications have been 
reported. However, as much as one fifth of PUD cases are H.pylori and NSAID 
negative (Charpignon et al 2013). 
2.2.1 HELICOBACTER PYLORI INFECTION
The association between the H.pylori infection and peptic ulcer formation was 
discovered in the early 1980s (Marshall and Warren 1984). The prevalence of 
H.pylori infection has declined in the Western world during the last decades (Pérez-
Aisa et al. 2005, McJunkin et al. 2011, Leow et al. 2016), although its prevalence 
is higher in lower socioeconomic conditions (Suerbaum and Michetti 2002). 
More than a half of the world´s population is estimated to be infected (Hooi et al. 
2017). Besides being an important factor in ulcer formation, the H.pylori infection 
increases the risk of peptic ulcer bleeding (PUB) (Udd et al. 2007, Nagata et al. 
2015, Sostres et al. 2015).
The seroprevalence of the H.pylori infection in the general population in younger 
birth cohorts in Finland was significantly lower in 1994 compared to that in 1974 
(Kosunen et al. 1997). The population-based voluntary “screen-and-treat” study 
among young adults aged 15-40 was carried out in Vammala, Finland, where 
12% of all the participants were seropositive in 1996, and 91% of them showed a 
diagnostic fall of antibody titers within half a year (Rautelin and Kosunen 2004). 
In a subcohort of participants aged 15 years the seroprevalence of H.pylori infection 
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was low and decreased from 3 to 2% during 1997-2000, and a decrease from 
27% to 12% occurred among the participants aged 45 years during the same time 
(Salomaa-Räsänen et al 2010). According to the Maastricht V/Florence consensus 
Report on H.Pylori infection, the test-and-treat strategy is nowadays recommended 
for young adults with persistent dyspepsia in primary care (Malfertheiner et al. 
2017). The test-and-treat policy is applied to dyspepsia patients up to 55 years in 
many developed countries, if no alarming symptoms such as weight loss or anemia 
emerge (Malfertheiner et al. 2009, Lanas and Chan 2017).
The prevalence of H.pylori infection in PUD patient cohorts has varied from 
as low as 9% in the USA (Parasa et al. 2013), to 60% in France (Charpignon et al. 
2013). Approximately 80% of infected individuals are symptomless (Sachs et al. 
2011), and the life-time risk of developing PUD varies from 3% to 25% (Suerbaum 
and Michetti 2002, Maltferheiner et al. 2009). Both the virulence of H.pylori and 
characteristics of an infected individual affect PUD development (Rautelin and 
Kosunen 2004). The reasons for PUD to develop in only some infected individuals 
are not known completely. Patients with H.pylori antral gastritis and high acid 
output are more prone to develop duodenal ulcers.
2.2.2 NON-STEROIDAL ANTI-INFLAMMATORY DRUGS
The use of NSAIDs is becoming a more significant risk factor for PUD. The use of 
NSAIDs in Finland has increased significantly from the 1990s (Figure 1), as well 
as in other countries (Higham et al. 2002, Bardhan et al. 2004, Pérez-Aisa et al. 
2005, Kang et al. 2006). In developed countries, one fourth of elderly patients use 
NSAIDs (Barat et al. 2000, Turunen et al. 2005, Sayer et al. 2010). An adverse 
effect of NSAIDs is one of the most common causes of drug side-effects requiring 
hospital admission, especially among the elderly (Sostres et al. 2009), with notable 
economic costs (Laine 2003). In one Finnish survey, 12% of adults aged 60 to 74 
used prescribed NSAIDs daily, and in the same group, 9% often took at the same 
time both prescribed and over-the-counter (OTC) NSAIDs (Turunen et al. 2005).
The risk of PUB among non-aspirin NSAID users is influenced by an individual 
NSAID used. The risk was reported to be at its lowest with the use of aceclofenac 
(Relative risk (RR) 2.6; 95%CI 1.5-4.6), diclofenac (3.1; 2.3-4.2) or ibuprofen (4.1; 
3.1-5.3) compared to ketorolac (14.4; 5.2-39.9) (Lanas et al. 2006). The concomitant 
use of NSAID and ASA increased the risk of PUB as well as the use of other 
bleeding-related drugs (Table 2). 
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The risk of PUB among non-aspirin NSAID users is influenced by an individual 
NSAID used. The risk was reported to be at its lowest with the use of 
Figure 1. Consumption of anti-inflammatory analgesics (M01A) in Finland during 1990-2015 (Finnish 
Medicines Agency and Social Insurance Institution 2016) by permission from FIMEA/Tinna Voipio.
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The use of low-dose ASA alone has been shown to increase the risk of acute 
upper GIB (Hallas et al. 2006, García Rodrígues et al. 2011). The risk of PUB in 
H.pylori positive patients who use NSAIDs is markedly increased (RR 8.0; 5.0-
13) as well as among patients who use only low-dose ASA (3.5; 2.6-6.1) compared 
t0 patients who are H.pylori negative and do not use NSAID/ASA (Sostres et al. 
2015). The use of NSAIDs also increases the risk of ulcer perforation (Svanes 2000, 
Søreide et al. 2014, Chung and Shelat 2017).  
The cyclo-oxygenase-2 (COX-2) selective inhibitor, celecoxib, was introduced 
to the market in 1999. The COX-2 selective inhibitors do not disturb the cyclo-
oxygenase-1 (COX-1) enzyme involved in gastrointestinal (GI) mucosal protection 
and platelet function, while inflammation and pain mediated by prostaglandin 
synthesis dependent on the COX-2 enzyme are deprived. In a control-case study 
from Spain during 2001-2004, the use of any coxib was not associated with PUB 
(RR 1.5; 95%CI 0.9-2.4), whereas the use of rofecoxib slightly increased the risk of 
PUB (2.1; 1.1-4.0) (Lanas et al. 2006). According to Cochrane´s systematic review of 
69 studies included, the risk of gastroduodenal ulcer complications was significantly 
lower (RR 0.39; 0.31-0.50) in COX-2 users than in nonselective NSAID users 
(Rostom et al. 2007). However, the rising concern about the increased risk of 
cardiovascular side-effects among COX-2 selective NSAID users (Mukherjee et 
al. 2001) eventually led to the withdrawal of rofecoxib from the market in 2004 
followed by valdecoxib the next year. 
In more recent analysis, the risk of cardiovascular events among COX-2 users 
and traditional NSAID users showed no difference; except in patients who used 
naproxen, for whom no excess of cardiovascular risk was shown (Kearney et al. 
2006). In a very recent study from Hong Kong, patients who were hospitalised for 
PUB and required both ASA and NSAID therapy for comorbidities were randomised 
for further medication of celecoxib+esomeprazol or naproxen+esomeprazol to 
compare the occurrence of rebleeding (Chan et al. 2017). The cumulative incidence 
of rebleeding was significantly higher in the naproxen users with no difference in 
cardiovascular events.
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2.2.3 OTHER ASSOCIATED DRUGS
The use of selective serotonin reuptake inhibitors (SSRIs) was associated with 
only a slightly increased risk of PUB (or hemorrhagic gastritis) in a Danish 
population-based case-control study (Odds ratio OR 1.7; 1.01-5.1) (Dall et al. 2009). 
In that study, the risk of bleeding was clearly higher among SSRI users if they 
used NSAIDs (8.0; 4.8-13) or NSAIDs and ASA (28; 7.6-103) concomitantly. The 
exact mechanism of a SSRI affecting the risk of bleeding is unknown, but possible 
mechanisms are their ability to inhibit platelet aggregation and induce gastric acid 
secretion (Jiang et al. 2015, Laursen et al. 2017a). In a large multinational study, 
the risk of upper GIB among patients on SSRI monotherapy was increased (RR 
2.1; 95%CI 1.9-2.2) with an increased risk of up to 7.0 (6.0-8.1) with a combination 
therapy of NSAIDs (Masclee et al. 2014). The risk of PUB was also reported to be 
increased in England among SSRI users after adjusting for all known risk factors 
for bleeding (OR 1.5; 1.3-1.7) (Crooks et al. 2013). Similar results were shown in a 
recent systematic review on the use of SSRI and the risk of upper GIB, where the 
risk of upper GIB was slightly increased among SSRI users (OR 1.6; 1.4-1.8), and 
the risk of bleeding was increased with concurrent use of NSAIDs (3.7; 3.0-4.7) or 
antiplatelet drugs (2.5; 1.7-3.6) (Jiang et al. 2015). However, the use of SSRI was 
not associated with endoscopy-refractory bleeding, rebleeding rate or short-term 
mortality in PUB patients in Denmark (Laursen et al. 2017a).
In one Spanish study, the use of oral corticosteroids was not associated with an 
increased risk of PUB (Lanas et al. 2006). On the contrary in England, the use of 
oral corticosteroids was associated with PUB when all the known risk factors for 
bleeding were adjusted (OR 1.3; 1.2-1.5) (Crooks et al. 2013). Similarly, the use of 
corticosteroids was associated with an increased risk of upper GIB (RR 4.1; 3.8-
4.3) (Masclee et al. 2014). In that study, the use of NSAIDs with corticosteroids 
was associated with a clearly elevated risk of bleeding (13; 11-15). In another 
study from Taiwan, the short-term use of glucocorticoids was associated with an 
increase risk of PUB (Tseng et al. 2015). The risk of PUB was higher with higher 
doses or with concomitant use of NSAIDs. Based on most published studies, 
the use of corticosteroids is generally regarded as a risk factor for PUD and its 
complications. However, based on a recently published systematic review, the risk of 
gastrointestinal bleedings and perforations was increased only among hospitalised 
patients (Narum et al. 2014). 
In a large multinational study, the risk of acute upper GIB was increased with the 
monotherapy use of calcium channel blockers (RR 1.6; 95%CI 1.5-1.6), nitrates (2.6; 
2.4-2.7) and aldosterone antagonists (3.3; 3.1-3.5) (Masclee et al. 2014). The use of 
NSAIDs or coxibs concomitantly with those drugs increased the risk significantly 
with the highest in patients using combination of an aldosterone antagonist and 
NSAID (11; 8.6-14). However, in another hospital-based case-control study of only 
PUB patients, no association between PUB and the use of angiotensin converting 
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enzyme (ACE) inhibitors, angiotensin II receptor blockers, calcium channel blockers 
or α/β-blockers occurred (Nagata et al. 2015). 
The use of newer non-vitamin K antagonist oral anticoagulants (NOACs) is 
increasing; the use of clopidogrel (defined daily dose (DDD)/1000 inhabitants) 
increased by 9% in 2015 in Finland (Finnish Medicines Agency Fimea and Social 
Insurance Institution 2016). Not all newer NOACs have specific antidotes when 
acute bleeding occurs, and that might complicate the management of acute 
bleeding. The use of NOACs was associated with a slightly increased risk of acute 
GI bleeding compared to the patients with traditional anticoagulants (OR 1.16; 1.00-
1.34) (Holster et al.2013). In that review, the prevalence of GI bleedings was low 
(0.1-0.2%) in the trials on thromboprophylaxis after orthopedic surgery, whereas 
in trials on treatment of acute coronary syndrome 5.3% of patients on NOACs had 
GI bleeding compared to 1.0% among controls having placebo in addition to the 
standard platelet therapy. When analysing different drug groups separately, the use 
of dabigatran or rivaroxaban was associated with an increased risk of bleeding but 
the risk of bleeding did not increase among apixaban users. In a systematic review 
published in 2015, the risk of overall GI bleeding was not significantly increased 
among patients using NOACs compared to patients using other anticoagulant drugs 
with a known increased risk of GI bleeding (Caldeira et al. 2015). In a Swedish 
retrospective cohort study of atrial fibrillation patients starting anticoagulation with 
either a NOAC or warfarin during 2011-2014, no difference in incidence of GIB 
occurred but the risk of intracranial bleeding and other major bleedings requiring 
hospitalisation was significantly higher in warfarin users (Sjögren et al. 2017). 
No statistically significant difference in all-cause mortality was shown between 
NOAC and warfarin users in that study. On the other hand, in a recently published 
study from the USA, patients on warfarin experienced significantly more often GIB 
leading to hospitalisation than the NOAC users (2.5% vs 0.6%; OR=4.1, 95% CI 
1.7-10.1) (Cangemi et al. 2017).     
2.2.4 AGE AND LIVING HABITS
The incidence of PUD and its complications is increased by age (Svanes 2000, 
van Leerdam et al. 2003). The previous history of PUD is a significant risk factor 
for recurrence (Sostres et al. 2015). Female gender decreased the risk of PUB in 
Spain (adjusted RR 0.36; 0.31-0.42) (Lanas et al. 2006). This was similarly shown 
in Korea, where male gender increased the risk of PUB (OR 1.78; 1.10-2.89) (Kang 
et al. 2011).
Smoking increases the risk of PUD (Aro et al. 2006, Lanas et al. 2006, Sostres 
et al. 2015). Smoking was a dose-dependent risk factor for PUB in Finland, whereas 
the use of alcohol was not (Udd et al. 2007). Contradictory results to that Finnish 
study have been reported from Asia, where alcohol use was associated with PUB, 
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but no association was found between smoking and PUB (Kang et al. 2011, Nagata 
et al. 2015). Smoking has also been shown to be a risk factor for ulcer perforation 
(Svanes 2000). Obesity was associated with an increased risk of uncomplicated 
gastric ulcer in a Swedish population-based study (Aro et al. 2006).
In recent studies, psychological stress and dramatic changes in living conditions, 
such as experiencing a life-threatening earthquake or accommodation in a refugee 
shelter, is also associated with formation of PUD (Malfertheiner et al. 2009, 
Yamanaka et al. 2013, Kanno et al. 2015, Levenstein et al. 2015). The use of a 
gastroprotective agents, commonly PPIs, as stress ulcer prophylaxis in all critically 
ill patients in the intensive care units have been standard care until recently, 
with concerns about its necessity for all patients or possible associated harms 
(nosocomial pneumonia, Clostridium difficile infection or cardiovascular events) 
(Marker et al. 2017). 
2.2.5 COMORBIDITY
Comorbidity (e.g. rheumatoid arthritis, liver cirrhosis, renal insufficiency) is 
associated with occurrence of PUD complications and their recurrence (Lau et al. 
2011) and is an independent risk factor for PUB (Crooks et al. 2013, Nagata et al. 
2015). Comorbidity can be defined as the existence of a certain comorbidity, e.g. 
congestive heart failure, or using the well-validated Charlson comorbidity index 
(CCI) (Charlson et al. 1987). In a Danish observational study, PUB patients had 
a significantly higher level of comorbidities compared to the age- and gender-
matched control cohort (mean CCI 0.92 vs o.49, p<0.001) (Laursen et al. 2015a). 
2.2.6 RARE DISEASES
A gastric or duodenal ulcer can be a clinical manifestation for some rare diseases. An 
anastomotic peptic ulcer after subtotal gastric resection is one manifestation of PUD 
and is also referred to as a marginal ulcer. With multiple ulcers or an ulcer occurring 
in the more distal duodenum than the bulbus,  Zollinger-Ellison syndrome (acid 
hypersecretory syndrome), Crohn´s disease, ischemia or underlying malignancy 
should be considered (Maltferheiner et al. 2009). At least for patients suffering a 
recurrent ulcer with no common risk factors, the possibility of rare disease should 
be excluded. 
Other rare specific causes of PUD are eosinophilic gastroduodenitis, systemic 
mastocytosis, radiation damage, viral infections (cytomegalovirus and herpes 
simplex, particularly in immunosuppressed patients), colonisation of stomach with 
Helicobacer heilmanii and Cameron ulcer (gastric ulcer where a hiatus hernia 
passes through the diaphragmatic hiatus) (Maltferheimer et al. 2009). Some 
patients have hyperfunctional antral G-cells leading to acid hypersecretion and 
ulcer formation. Additionally, mechanical obstruction (e.g. batteries) can lead to 
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an ulcer formation. Ingested batteries may also induce ulcer formation by leaking 
the battery contents or generating an external electric current. Abuse of crack 
cocaine can also cause peptic ulcer formation emerging as peptic ulcer perforation 
(Schuster et al. 2007).
2.2.7 IDIOPATHIC ULCER
The peptic ulcer is considered idiopathic, when no risk factor for an ulcer formation 
exists. The pathogenic mechanisms associated with the development of an 
idiopathic ulcer are unknown (Lanas and Chan 2017).
2.3 PATHOPHYSIOLOGY
PUD develops when the protective mechanisms of the gastrointestinal mucosa 
are disturbed. Several different exogenous and endogenous mechanisms affect the 
secretion of hydrochloric acid, pepsin and mucus. Secretion of gastrin, histamine and 
acetylcholine stimulates the secretion of hydrochloric acid, whereas somatostatin 
and secretin are inhibitors. Sense of food activates secretion of hydrochloric acid 
by stimulating the vagus nerve. Hydrochloric acid converts pepsinogen to pepsin. 
Mucus and bicarbonate are secreted from the mucus cells to prevent damage in 
the gastric epithelium. 
Peptic ulcers occur mainly in the stomach or proximal duodenum. Peptic 
ulcer can be defined as a break in the mucosa of ≥5mm in diameter covered 
with fibrin, and it invades the muscularis mucosa according to the pathological 
criterion (Kumar et al. 1997, Hsu et al. 2001, Maltferheiner et al. 2009). The 5mm 
criterion is arbitrary, but is usually used in clinical trials and endoscopy reports. 
The smaller lesions are usually called erosions. Naturally, the medium pH level 
of the stomach is 1.4 varying from <1.o to 5.0 regarding to ingestion of food and 
fasting (Sachs et al. 2011). Besides the H.pylori infection and the use of NSAIDs, 
a decrease in circulation can lead to an impairment of the mucosal barrier. After 
the impairment of the mucosal barrier, hydrochloric acid and pepsin induce ulcer 
formation. However, the development of different types of peptic ulcers is not 
completely understood (Lanas and Chan 2017).
2.3.1 H.PYLORI INDUCED ULCER
H.pylori is able to acclimate in the highly acid environment of the stomach (Sachs 
et al. 2011). With the help of urease in the bacterial cytoplasm, it manages to 
maintain a cytoplasmic pH high enough to survive in an acidic environment. The 
ability of motility and binding tightly to gastric epithelial cells also helps colonisation 
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(Suerbaum and Michetti 2002). After binding to the epithelial cells, H.pylori causes 
gastric inflammation by activation of leukocytes, interleukins, and systemic and 
mucosal humoral responses. Epithelial injury can also occur from reactive oxygen 
and nitrogen species by activated neutrophils. This leads to the eruption of the 
mucosal barrier that allows acid and pepsins to invade through the epithelial cell 
to cause an ulcer (Figure 2). The usual site of infection is in the antrum of stomach, 
but under the PPI treatment with an increase in the pH of the antrum, the organism 
is found more probably in the fundus.  Patients with corpus-predominant gastritis 
and with a lower level of acid produce are more prone to gastric ulcers. The H.pylori 
infection in the antrum leads to inhibition of somatostatin secretion form the D 
cells. That causes an increase in acid secretion, inducing gastric metaplasia in the 
bulb of duodenum and enables the colonisation of H.pylori there. 
Normal gastric mucosa
Helicobacter pylori infection
Antral-predominant
gastritis
Corpus-predominant
atrophic gastritis
Individually high level of
acid production
Individually low level of 
acid production
Duodenal ulcer Gastric ulcer
Somatostatin↓
Gastrin↑
Acid secretion↑
Asymptomatic H.pylori infection
Nonatrophic pangastritis
H.pylori virulence + Host
(genetic, ethnic, environmental, 
sosioeconomic) factors
→Inflammation reactions
Gastric metaplasia in
duodenum
Figure 2. Pathogenesis of Helicobacter pylori positive ulcers.
2.3.2 NSAID INDUCED ULCER 
The mechanisms of an NSAID induced ulcer can be divided into topical injury and 
systemic mechanisms (Wolfe et al. 1999, Chan 2005, Musumba et al. 2009). The 
systemic effects include suppression of gastric prostaglandins synthesis through 
cyclooxygenase inhibition, which is considered to be the main mechanism of 
mucosal damage (Lanas and Chan 2017), and prostaglandin-independent effects 
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including upregulating of mucosal pro-inflammatory mediators. Prostaglandin 
inhibition leads to decreases in mucus and bicarbonate secretion, mucosal blood 
flow and epithelial proliferation, which leads to degradation of mucosal resistance 
on endogenous and exogenous factors. NSAIDs can directly affect gastric epithelial 
cells causing general damage or dysfunction via multiple cellular and molecular 
mechanisms that might lead to necrosis and apoptosis (Musumba et al. 2009). The 
consistency of the gastric mucosal barrier is dependent on continuous generation of 
prostaglandin E2 and prostacyclin requiring COX-1 and COX-2. The use of NSAIDS 
induces ulcer formation by COX inhibition. The use of COX-2 selective NSAIDs, i.e. 
coxibs, decreases the rate of endoscopic ulcers as compared to traditional NSAIDs 
(Laine 2003). The COX-2 derived prostaglandins, however, play an important role 
in ulcer healing (Musumba et el. 2011). The use of ASA induces mucosal damage 
mainly through topical mechanisms (Lanas and Chan 2017). The mucosal injury 
is caused by acidic effects of ASA and other NSAIDs (Wolfe et al. 1999). The use of 
enteric-coated ASA prevents topical injury, but even small doses of ASA suppress 
prostaglandin synthesis. Therefore, no difference in the risk of major upper GI 
bleedings occurs between the users of enteric-coated or buffered ASA compared 
to the users of plain ASA (Laine 2003). 
2.4 CLINICAL MANIFESTATION
2.4.1 SYMPTOMS
Symptoms of peptic ulcers vary in individual patients not forgetting that some 
patients are symptomless. Upper abdominal pain is the most common symptom. 
Besides pain, patients can suffer from epigastric burning, postprandial fullness, 
bloating, nausea and vomiting. None of the symptoms is pathognomonic for PUD. 
Patients with duodenal ulcers typically feel hungry or have nocturnal abdominal 
pain, whereas postprandial abdominal pain, nausea, vomiting and weight loss are 
associated with gastric ulcers (Lanas and Chan 2017). 
Elderly patients with PUD are frequently symptomless or have only mild 
symptoms, and the first manifestation of complicated peptic ulcer may lead to 
hospitalisation with marked morbidity and mortality. The long-lasting use of 
NSAIDs for chronic pain, impaired protective mechanisms of the gastrointestinal 
mucosa, and comorbidities are factors that make the elderly more vulnerable to 
PUD formation (Zullo et al. 2007).   
Melena and hematemesis are common symptoms among PUB patients. 
Occasionally, only a drop in the hemoglobin level causes dizziness or tachycardia 
that leads to a PUB diagnosis. The classic triad of sudden onset of abdominal pain, 
tachycardia and abdominal rigidity or signs of peritonitis is representative for 
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perforation of peptic ulcer (PPU). After perforation, gastric juice and gas enters the 
peritoneal cavity leading to chemical peritonitis. In the following hours, chemical 
peritonitis progresses to bacterial peritonitis due to gut flora.    
2.4.2 LOCATION
Of all peptic ulcers, most appear either in the first part of the duodenum or in the 
stomach, in a ratio of about 4:1 (Kumar et al. 1997). Another rare location of a 
peptic ulcer is appearing in the Meckel´s diverticulum.  
The prevalence of duodenal ulcers among PUB patients has been higher than 
that of gastric ulcers (Pérez-Aisa et al. 2005, Lanas et al. 2006, Bardhan and 
Royston 2008, Sadic et al. 2009, Bakkevold 2010, Sung et al. 2010, Rosenstock 
et al. 2013), but contradictory results have emerged (Smith and Stabile 2005, 
Åhsberg et al. 2011, de Groot et al. 2014). The prevalence of gastric ulcers was 53% 
in H.pylori –negative idiopathic ulcer cohort, whereas among H.pylori –positive 
ulcer cohort 63% had duodenal/gastroduodenal ulcers in Taiwan (Wong et al. 
2009). However, the peptic ulcer cases were evenly distributed in a Spanish PUB 
cohort 2006-2012 (Sostres et al. 2015).
2.5 DIAGNOSIS
2.5.1 OESOPHAGOGASTRODUODENOSCOPY (OEGD)
The diagnosis of PUD can be made endoscopically, when the location, appearance 
and size of an ulcer is defined. Therefore, OEGD is the gold standard for diagnosis 
of PUD. Patients with upper GIB symptoms should be referred for endoscopy 
within 24h after admission (Barkun et al. 2010, Gralnek et al. 2015). However, 
the proportion of patients with acute upper GIB experiencing OEGD in the 
recommended time frame has varied from 50% in the UK in 2007 (Hearnshaw 
et al. 2010) to 76% in Canada during 1999-2002 (Barkun et al. 2004) and 81% in 
Italy 2007-2008 (Marmo et al. 2010).
2.5.1.1 Symptoms leading to acute oegd
Patients are admitted to acute OEDG during the hospitalisation for various 
symptoms. Symptoms of acute bleeding, i.e. hematemesis or melena, are the most 
common indications, but patients with acute anemia, severe dysphagia, epigastric 
pain or suspicion of a foreign body are also referred for acute OEGD.
24
2.5.2 DIAGNOSIS OF PERFORATED PEPTIC ULCER
Patients with acute PPU are usually admitted to emergency departments with 
severe epigastric pain. Other symptoms as severe dyspepsia, abdominal distension, 
nausea, fever, tachycardia and hypotension may occur (Chung and Shelat 2017). 
Traditionally, free air under the diaphragm on an erect chest X-ray with upper 
abdominal pain symptoms suggests a diagnosis of PPU. However, in 25-40% of 
patients with PPU free air on the X-ray is not revealed (Grassi et al. 2004, Thorsen 
et al. 2011, Anbalakan et al. 2015). The gold standard nowadays is a computed 
tomography (CT) scan with a diagnostic accuracy as high as 98% (Thorsen et 
al. 2011, Kim et al. 2014). In addition, with the help of a CT scan and serum 
amylase, acute pancreatitis can be ruled out among patients with severe upper 
abdominal pain.  
2.5.3 GASTRIC BIOPSY SPECIMENS AND TESTS FOR H.PYLORI INFECTION
During OEGD, biopsies are usually taken to exclude malignant ulcers and to 
demonstrate the H.pylori infection among patients with gastritis. In addition to 
histology biopsies, H.pylori infection can be diagnosed by non-invasive methods 
such as serology, urea breath test and stool antigen test (Rautelin and Kosunen 
2004). The sensitivity of serological tests on H.pylori IgG antibodies based on 
enzyme immunoassay varies from 97% to 100% with specificity of 95-99% in 
Finland. The sensitivity and specificity of the urea breath test is more than 90% 
(Suerbaum and Michetti 2002).  
2.6 DIFFERENTIAL DIAGNOSIS
2.6.1 CAUSES FOR UPPER GASTROINTESTINAL BLEEDING
Acute GI bleeding is one of the most common medical emergencies leading to 
hospitalisation with notable costs (Peery et al. 2015). The overall incidence of upper 
GI bleeding has varied from 45 per 100 000 inhabitants per year to 160 per 100 
000 (Vreeburg et al. 1997, Paspatis et al. 2000, Åhsberg et al. 2010a, Button et al. 
2011). Most patients are referred for acute OEDG for diagnosis (Table 3).
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Table 3. Etiology (%) of acute upper GI bleeding.
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Table 3. Etiology (%) of acute upper GI bleeding. 
Etiology Vreeburg et 
al. (1997) % 
Leerdam et 
al. (2003) % 
Loperfido et 
al. (2009) % 
Nahon et al. 
(2012) % 
Miilunpohja et 
al. (2017) % 
PUD 39 46 53 31 50 
Erosive 6 -- 10 7 -- 
Mallory-Weiss 5 -- 3 7 8 
Variceal 
bleeding 
8 7 12 21 8 
Oesophagitis 7 -- 4 13 17 
Gastroduodenal 
lesions* 
-- 20 -- -- -- 
Neoplasm 3 5 5 3 4 
Other 8 8 8 13 -- 
No finding 24 14 5 5 13 
*Includes oesophagitis, Mallory-Weiss, erosions, gastroduodenitis 
2.6.2 PATIENTS PRESENTING WITH ACUTE UPPER 
GASTROINTESTINAL BLEEDING WITH NO FINDING IN 
OEGD 
 
The proportion of patients with acute GI bleeding symptoms without a 
known source in OEGD has varied from 5% (Nahon et al. 2012) to 32% 
(Sengupta et al. 2016) in previous studies. The most common sources for 
acute lower GI bleeding in the previous studies were diverticulosis, ischemic 
colitis, hemorrhoids and colon cancer (Longstreth 1997, Arroja et al. 2011, 
Hreinsson et al. 2013). In those lower GI bleeding studies, no source for 
bleeding was diagnosed in 8-12% of patients. 
2.6.3 MALIGNANT ULCERS 
 
A bleeding ulcer can be the first symptom of gastric cancer. The H.pylori 
infection is a risk factor for both PUD and gastric cancer (Tsuda et al. 2017). 
In a large cohort study of hospitalised gastric ulcer patients in Sweden during 
1965-1983, the risk for gastric cancer was nearly 10-fold during the first three 
years of follow-up, and it remained two-fold during the follow-up as long as 
24 years for the same patients (Hansson et al. 1996). In a Taiwanese cohort 
study during 1997-2004, the risk for gastric cancer development was 
increased in gastric ulcer patients compared to duodenal ulcer patients (HR 
2.9; 2.1-3.9) (Wu et al. 2009). According to that study, other independent 
risk factors for gastric cancer development were older age, male gender and 
2.6.2 PATIENTS PRESENTING WITH ACUTE UPPER GASTROINTESTINAL  
 BLEEDING WITH NO FINDING IN OEGD
The proportion of patients with acute GI bleeding symptoms without a known 
source in OEGD has varied from 5% (Nahon et al. 2012) to 32% (Sengupta et al. 
2016) in previous studies. The most common sources for acute lower GI bleeding 
in the previous studies were diverticulosis, ischemic colitis, hemorrhoids and colon 
cancer (Longstreth 1997, Arroja et al. 2011, Hreinsson et al. 2013). In those lower 
GI bleeding studies, no source for bleeding was diagnosed in 8-12% of patients.
2.6.3 MALIGNANT ULCERS
A bleeding ulcer can be the first symptom of gastric cancer. The H.pylori infection 
is a risk factor for both PUD and gastric cancer (Tsuda et al. 2017). In a large 
cohort study of hospitalised gastric ulcer patients in Sweden during 1965-1983, the 
risk for astric cancer was nearly 10-fold during the fir  three years of follow-up, 
and it remained two-fold during the follow-up as long as 24 years for the same 
patients (Hansson et al. 1996). In a Taiwanese cohort study during 1997-2004, 
the risk for gastric cancer development was increased in gastric ulcer patients 
compared to duodenal ulcer patients (HR 2.9; 2.1-3.9) (Wu et al. 2009). According 
to that study, other independent risk factors for gastric cancer development were 
older age, male gender and presence of complicated peptic ulcer at the index 
hospitalisation. The frequent use of ASA/NSAIDs and early H.pylori eradication 
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therapy was associated with a decreased risk of cancer. The H.pylori infection is 
also a known risk factor for mucosa-associated lymphoid tissue (MALT) lymphoma 
(Rautelin and Kosunen 2004). Therefore, proper healing of a gastric ulcer should 
be confirmed endoscopically after appropriate PPI therapy and H.pylori infection 
eradication therapy given when necessary. The reported proportion of patients 
having malignant gastric ulcer perforation varies from 10% to 16% (Ergul and 
Gozetlik 2009).
2.7 COMPLICATIONS
2.7.1 INCIDENCE OF COMPLICATIONS
The proportion of patients suffering complicated PUD differs in published studies. 
The annual number of hospital admission for complicated PUD (hemorrhage, 
perforation and stenosis) in Finland increased significantly from 38 per 100 000 in 
1972-1976 to 69 per 100 000 in 1992-1996 (Paimela et al. 2002). The incidence of 
bleeding peptic ulcers remained stable in Denmark 1993-2002, while the incidence 
of perforated ulcers decreased (Lassen et al. 2006). The incidence of all PUD 
complications decreased from 109 to 81 per 100 000 in Spain during 1990-2000 
(Pérez-Aisa et al. 2005). The decreasing trend for PUD complications is shown 
studies published over the last ten years (Kang et al. 2006, Sadic et al. 2009, Lanas 
et al. 2011, Laine et al. 2012).
2.7.2 BLEEDING ULCER
PUB is the most common complication in PUD patients (Pérez-Aisa et al. 2005, 
Lau et al. 2011) with decreasing incidence (Wang et al. 2010, Åhsberg et al. 2010b, 
Lanas et al. 2011). The incidence of PUB varies from 19 per 100 000 in the UK 
(Bardhan et al. 2004) t0 80 per 100 000 (69-92) in Spain 2000 (Pérez-Aisa et 
al. 2005) (Table 4).
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Table 4. Incidence of peptic ulcer bleeding.
Reference Country Year(s) Incidence 
per 100 000 
inhabitants
Bardhan et al. 2004 United Kingdom 1995-2000      19
Ramsoekh et al. 2005 the Netherlands 2000      22
Åhsberg et al. 2010 Sweden 2004      32
Laine et al. 2012 USA 2009      32
Bakkevold 2010 Norway 2007-2008      45
Ohmann et al. 2005 Germany 1999-2000      49
Soplepmann et al. 1997 Estonia 1992-1993      57
Lassen et al. 2006 Denmark 2002      57
Pérez-Aisa et al. 2005 Spain 2000      80
Bleeding peptic ulcers are usually categorised according to the Forrest 
classification (Forrest et al. 1974) with differences in rebleeding and mortality 
rates (Table 5). The reported rebleeding rates and mortality were based on older 
publications when patients did not receive endoscopic therapy (Laine and Petersen 
1994). Based on the Forrest classification, ulcers can nowadays be categorised 
based on their need for endoscopic therapy as 1) major stigmata of ulcer bleeding 
(Forrest Ia-IIb), or 2) minor stigmata of ulcer bleeding (Forrest IIc or III). 
Table 5. The Forrest classification of peptic ulcer bleeding, rebleeding rate and associated mortality 
(Laine and Peterson 1994). 
Classification Definition Rebleeding rate 
% (range) 
Mortality 
% (range)
Ia Spurting haemorrhage 55 (17-100) 11 (0-23)
Ib Oozing haemorrhage 55 (17-100) 11 (0-23)
IIa Visible vessel 43 (0-81) 11 (0-21)
IIb Adherent clot 22 (14-36)  7 (0-10)
IIc Haematin on ulcer base 10 (0-13)  3 (0-10)
III Clean base ulcer   5 (0-10)  2 (0-3)
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In a recent published study, the rebleeding rates of peptic ulcers by Forrest 
classification after successful endoscopic hemostasis but with no PPI therapy were 
23% in Ia ulcers, 5% in Ib, 11% in IIa, and 18% in IIb, respectively, suggesting that 
Ib ulcers after initial endoscopic management should not be categorised as major 
stigmata of hemorrhage (Jensen et al. 2017). In another study from the Netherlands 
during 2009-2012, the overall rebleeding rate was quite high (19%) varying from 
59% among Forrest Ia ulcers to 7% in Forrest III ulcers (de Groot et al. 2014). In that 
study, only 70-74% of patients were treated with dual therapy in endoscopy. Based 
on a systemic review of 28 studies, the recurrent rate of all bleeding ulcers after 
successful initial endoscopic hemostasis has varied from 0-38%, being on average 
at 10% (Lau et al. 2011). In a recently published study from Finland, 4.4% of PUB 
patients hospitalised during 2000-2015 needed a secondary procedure for bleeding, 
and 1.0% were admitted to prophylactic transcatheter arterial embolisation (TAE) 
(Nykänen et al. 2017).
2.7.3 PERFORATED ULCER
The incidence of peptic ulcer perforations was 8 per 100 000 (5-13) in Spain 2000 
(Pérez-Aisa et al. 2005) as well as in Sweden 2005 (Åhsberg et al. 2011).  The 
hospitalisation rates of patients with PPU decreased significantly from 17 to 12 per 
100 000 in Denmark during 1996-2oo4 (Christensen et al. 2007). The estimated 
annual incidence of peptic ulcer perforation is 3.8-14 per 100 000 individuals 
(Lau et al. 2011). The annual operation rate for PPU was 3.6 per 100 000 in the 
Northern Finland in 2000, with no significant change during 1979-2000 (Mäkelä et 
al. 2002). Recently, a relative increase in PPU among elderly women has occurred, 
while the incidence of duodenal ulcer perforations among young men has decreased 
(Svanes 2000).
2.7.3 OTHER RARE COMPLICATIONS
Rare complications of PUD are pylorus obstruction and penetration or fistula to 
another organ e.g. pancreas. The incidence of gastric outlet obstruction decreased 
from 6.8 per 100 000 (95% CI: 4.0-10.9) in 1985 to 1.7 per 100 000 (0.5-4.3) in 2000 
in Spain (Pérez-Aisa et al. 2005). Of all PUD hospitalisation in the United States 
in 2006, 2.9% of patients had obstruction (Wang et al. 2010). After introduction 
of H.pylori eradication therapy and PPIs, other benign and malignant diseases 
than PUD usually cause gastric outlet obstruction (Johnson and Ellis 1990, Rana 
et al. 2011). PUD is an underlying cause of only up to 8% of patients presenting 
with gastric outlet obstruction (Napolitano 2009).
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2.8 MANAGEMENT
Patients presenting with acute peptic ulcer bleeding or perforation should be 
assessed promptly and resuscitated before definitive management. International 
guidelines recommend a strict policy for blood transfusions with recommendation 
of a hemoglobin target level of 70 g/l (Barkun et al. 2010). Mortality among PUB 
patients with restrictive strategy showed a trend toward better survival (HR 0.70; 
0.26-1.25), although it was not statistically significant, as was seen when all the 
patients admitted with severe acute upper GIB were analysed in Spain (0.55; 0.33-
0.92) (Villanueva et al. 2013). However, in that Spanish study, patients with massive 
exsanguinating bleeding, or severe comorbidity as an acute coronary syndrome, 
stroke or symptomatic peripheral vascular disease were excluded, and one third 
of the patients had cirrhosis. On the other hand, no differences in outcomes 
occurred in the UK when strictive and liberal transfusion policies were compared 
among upper GIB patients in the TRIGGER study that also excluded unstable 
patients at admission (Jairath et al. 2015). Coagulopathy and acute bleeding is a 
challenging clinical problem. The exact target level of the International Normalized 
Ratio (INR) of coagulation has not been defined, and it should depend on the 
individual patient´s indication for anticoagulation or existence of disease causing 
coagulopathy (Lau et al. 2013).     
The use of risk stratification scores is highly recommended (Barkun et al. 
2010, Jairath and Barkun 2012). The pre- and post-endoscopic Rockall scores, 
the Glasgow Blatcford score, or a newer AIMS65 score are suitable for PUB patients 
for dividing patients into low- and high-risk categories when predicting rebleeding 
or mortality (Rockall et al. 1996, Blatchford et al. 2000, Saltzman et al. 2011). The 
Boey´s score is commonly used among PPU patients (Boey and Wong 1987) to 
predict mortality based on a patient´s comorbidity, pre-operative shock and time 
from the onset of abdominal pain. The American Society of Anesthesiology score 
ASA is also useful in risk stratification for patients undergoing surgery (Saklad 
1941, Wolters et al. 1996).
Gastroprotective agents (GPAs) and endoscopic treatments are essential factors 
in PUD patient treatment, whereas surgery is needed in refractory bleeding or 
perforated cases. The utilisation of interventional radiology in PUB is emerging 
especially among fragile patients not suitable for surgery.   
2.8.1 GASTROPROTECTIVE AGENTS
The use of GPAs, mainly proton pump inhibitors (PPIs), has increased during 
the last decades in Finland (Figure 3) and other countries (Pérez-Aisa et al. 2005, 
Kantor et al. 2015). The introduction of histamine-2 (H2) –receptor antagonists 
occurred in 1980 and of PPIs (omeprazole) in 1988 in Finland. The PPIs are used to 
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provide neutral gastric pH, which enables a favorable milieu for clot formation. The 
use of other GPAs as H2-receptor antagonists, antacids, misoprostol, sucralfate, and 
alginic acids is nowadays diminutive compared to that of PPIs (Finnish Medicines 
Agency and Social Insurance Institution 2016).
The use of PPIs is associated with a significant reduced risk of bleeding as a 
PUD complication [RR 0.3; 95%CI 0.3-0.4 (Lanas et al. 2006), RR 0.4; 0.3-0.6 
(Sostres et al. 2015)]. The use of PPI with ASA or NSAIDs also reduced the risk of 
bleeding (Lanas et al. 2007). However, the monotherapy use of GPA was associated 
with a slightly increased risk of acute upper GIB in a multinational European study 
(IRR 1.6; 95%CI 1.6-1.7) (Masclee et al. 2014), indicating that patients at risk of 
bleeding are identified. In those patients with possible many known risk factors 
for bleeding, the use of GPA is not efficient enough for prevention.
The international guidelines recommend continuous intravenous PPI-treatment 
following the initial intravenous bolus for patients with high-risk stigmata of ulcer 
bleeding for the next 72 hours after the index endoscopy (Barkun et al. 2010, 
Gralnek et al. 2015). However, in a recent meta-analysis, no difference in rebleeding 
or mortality rate occurred among patients on oral or intravenous PPI (Tsoi et al. 
2013). A common clinical practise for years has been to change intravenous PPI to 
an oral one when the patient is able to eat and the possibility of re-endoscopy or 
surgery has faded. After the initial hospitalisation, PPIs are used to heal the ulcer 
completely and to prevent the recurrence. The duration of PPI treatment is usually 
4-8 weeks by clinical decision. According to a meta-analysis, the mean ulcer healing 
rate in H.pylori positive ulcers was 91% after a 7-day eradication therapy with PPI 
compared to 92% when PPI was used for 2-4 weeks more (Gisbert and Pajares 
2005). On the other hand, patients at high-risk for NSAID induced recurrent ulcers 
should continue PPI use if NSAIDs are needed for comorbidity; that also outweighs 
the possible risks associated with long-term use of PPI (Freedberg et al. 2017). 
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2.8.2 ERADICATION THERAPY FOR H.PYLORI 
 
A combination therapy of two antimicrobials (amoxicillin, clarithromycin, 
tetracycline or metronidazole) with PPI for one week is usually 
recommended to eradicate H.pylori infection in Finland (The Finnish 
Current Guideline by Working group appointed by the Finnish Medical 
Society Duodecim and the Finnish Society of Gastroenterology 2013). The 
use of a one-week combination package for Helicobacter pylori infection 
available at the Finnish pharmacies (ATC code A02BD) remained stable 
during 2010-2015 (Finnish Medicines Agency Fimea and Social Insurance 
Institution 2016). The first-line eradication therapy should succeed at least in 
80% of patients (Lanas and Chan 2017, Malfertheiner et al. 2017). The 
Finnish Current Care Guideline recommends amoxicillin and clarithromycin 
together with PPI for a week as a first-line eradication therapy (Working 
group appointed by the Finnish Medical Society Duodecim and the Finnish 
Society of Gastroenterology 2013). The eradication rate with that triple-
therapy in a Finnish study during 2000-2002 was 91% (Koivisto et al. 2005). 
The overall prevalence of metronidazole resistance was 40%, of 
clarithromycin 8% and of levofloxacin 7% in Finland during 2000-2008 
Figure 3. Consumption of gastroprotective agents in Finland during 1990-2015 (Finnish Medicines 
Agency and Social Insurance Institution 2016) by permission from FIMEA/Tinna Voipio.
2.8.2 ERADICATION THERAPY FOR H.PYLORI
A combi ation therapy of two antimicrobials (amoxicillin, clarithromycin, 
t tracycline or metronidazol ) with PPI for one week is usually recommended to
eradicate H.pylori infection in Finland (The Finnish Current Guideli e by Working 
group appointed by the Finnish Medical Society Duodecim and the Finnish 
Society of Gastroenterology 2013). The use of a one-week combination package 
for Helicobacter pylori infection available at the Finnish pharmacies (ATC code 
A02BD) remained stable during 2010-2015 (Finnish Medicines Agency Fimea 
and Social Insurance Institution 2016). The first-line eradication therapy should 
succeed at least in 80% of patients (Lanas and Chan 2017, Malfertheiner et al. 2017). 
The Finnish Current Care Guideline recommends amoxic llin and clarithromycin 
together with PPI for a week a  a first-line eradication th rapy (Working group
appointed by the Finnish Medical Society Duodecim and the Finnish Society of 
Gastroenterology 2013). The eradication rate with that triple-therapy in a Finnish 
study during 2000-2002 was 91% (Koivisto et al. 2005). The overall prevalence 
of metronidazole resistance was 40%, of clarithromycin 8% and of levofloxacin 
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7% in Finland during 2000-2008 (Kostamo et al. 2011). However, metronidazole 
resistance in vitro does not always lead to a treatment failure.
For the growing prevalence of antibiotic resistance worldwide, a longer 10-
day- or two-week therapy is nowadays recommended (Lanas and Chan 2017, 
Malfertheiner et al. 2017). That will probably also change recommendations in 
Finland. The antimicrobial resistance of H.pylori to clarithromycin is over 20% in 
most European countries; except in the Northern Europe where the prevalence of 
resistance is less than 10%. Therefore, the choice of first-line therapy in countries 
with a high level of antimicrobial resistance should be based on susceptibility 
tests, or at least on local recommendations based on resistance rates (Figure 4). 
The use of susceptibility tests in H.pylori infection after failed first-line eradication 
therapy could be beneficial.  
Clarithromycin resistance
< 15% ≥15% or not available
PPIx2
Amoxicillin 1gx2
Clarithromycin 500mgx2
for 7 days
PPIx2
Amoxicillin 1gx2
Levofloxacillin 500mgx2
for 7 days
H.pylori urea breath test or serology
H.Pylori positive
PPIx2, Bismuth 125mg 2x2 or 1x4, Tetracycline 250mgx4,
Metronidatzole 400mgx3 for 10 days
Figure 4. The recommendation for choosing Helicobacter pylori eradication therapy by clarithromycin 
resistance (Modified after Malfertheiner et al. 2017). 
The rate of success in eradication therapy can be increased by doubling the PPI 
dose, extending therapy duration to a maximum of 14 days, or using a quadruple 
non-bismuth- or bismuth-based therapy (PPI + amoxicillin + clarithromycin + 
metronidazole or PPI + bismuth + tetracycline + metronidazole). Bismuth is 
available in Finland with a special permit from FIMEA. The sequential therapy 
of a 5-day dual therapy with a PPI and amoxicillin followed by a 5-day triple 
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therapy with a PPI, clarithromycin and tinidazole/metronidazole is not anymore 
recommended (Lanas and Chan 2017). In challenging cases with multiple therapy 
failures, rifabutin-based therapy for 10 days leads to eradications rates of 60-
70%. However, rifabutin is not recommended for use in Finland. New promising 
results with a potassium-competitive acid blocker vonoprazan -based triple therapy 
(amoxicillin and clarithromycin/metronidazole) have reported from Japan with 
an eradication rate of 85-97% (Tanabe et al. 2017).
The success of eradication therapy should be controlled. The gold standard for 
post-treatment test is nowadays the urea breath test that should be used not until 
an interval period of four weeks after eradication therapy in order to avoid false 
results. A stool antigen test can also be used, but not earlier than after an interval 
period of 8 weeks. Patients with a complicated gastric ulcer, or in some complicated 
duodenal ulcers cases by clinical decision, are admitted for a control endoscopy, 
and the eradication of H.pylori can be confirmed by biopsies taken. The successful 
eradication of H.pylori infection is essential to decrease the risk of recurrence of 
PUD and its complications. However, according to Cochrane systematic review, 
the role of H.pylori eradication therapy in acute gastric ulcer healing compare to 
ulcer healing therapy only is controversial (Ford et al. 2016). On the other hand, the 
risk of gastric cancer development was significantly decreased among hospitalised 
PUD patients who received H.pylori eradication therapy within the following year 
compared to the patients who received their therapy later (Wu et al. 2009).  
2.8.3 ENDOSCOPIC THERAPY
The endoscopic therapy is recommended for ulcers with active bleeding or with 
a non-bleeding visible vessel or an adherent clot (Forrest Ia-IIb) for their risk of 
recurrent bleeding. The removal of an adherent clot (IIb) in search of an artery 
is suggested in some studies, and only when it is present the endoscopic therapy 
should be given (Lau et al. 2013, Lu et al. 2014). Among patients with haematin 
on ulcer base (IIc) or a clean base ulcer (III, see Figure) endoscopic therapy is 
not needed.
According to the international guidelines the dual therapy with epinephrine 
injection is recommended for reducing the risk of rebleeding, surgery and mortality 
(Barkun et al. 2010, Gralnek et al. 2015). The endoscopic treatment can be 
traditionally divided into injection, thermal and mechanical methods (Table 6). 
Recently, novel endoscopic topical hemostatic powders have come onto market 
(Lu et al. 2014). However, the proportion of patients receiving dual therapy for 
major stigmata of hemorrhages has been reported in some national audits to be 
as low as 34% in Canada, 35% in Italy and 38% in the UK (Barkun et al. 2004, 
Hearnshaw et al. 2010, Marmo et al. 2010).    
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Figure 5. Peptic ulcer with a clean fibrin base (Forrest III) (Picture from Martti Färkkilä, Helsinki University 
Hospital, Finland).
Table 6. Endoscopic treatment possibilities for bleeding peptic ulcers (Luet al. 2014).
Injection Thermal Mechanical
Epinephrine
Hypertonic saline
Sclerosants
   Polidocanol
   Ethanolamine
   Absolute alcohol
   Sodium tetradecyl sulfate
Tissue adhesives
   Cyanoacrylate
   Thrombin
   Fibrin
Contact electrocoagulation 
(=thermocoagulation)
   Monopolar
   Bipolar
   Multipolar
Noncontact thermal therapy
   Argon plasma coagulation
   
Endoclips
Over-the-scope clips
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2.8.4 SURGERY
The need for elective surgery has dramatically decreased due to efficient conservative 
treatments (Paimela et al. 2002). However, the need for emergency surgery for 
perforated ulcers and refractory rebleedings still exists. The need for emergency 
surgery due to PUB in Sweden decreased significantly over the years 1987-2004, 
while utilisation of endoscopic treatments increased (Sadic et al. 2009), as seen 
in other Western countries (Lau et al. 2013, Rosenstock et al. 2013). In a recently 
published study from the Netherlands, only 1.3% of PUB patients needed surgery 
(de Groot et al. 2014).
Superiority of open or laparoscopic surgery in acute PPU cases is unsettled. 
In the Cochrane systematic review of three randomised clinical trials on PPU 
patients with repair utilising an omentum patch or fibrin sealant, no statistically 
significant difference in complications or mortality occurred between the open 
and laparoscopic technique (Sanabria et al. 2013). In a retrospective study from 
Norway during 2003-2009, the laparoscopic surgery rate increased significantly 
over the study years (Thorsen et al. 2011). In that study, the operation time for open 
surgery was shorter than for laparoscopic surgery with no statistically significant 
differences in morbidity or mortality. Based on literature reviews, among patients 
with shock on admission, a delay in management (over 24h), age over 70 years, 
high American Society of Anesthesiologists (ASA) grade, and high Boey score are 
risk factors that advocate choice for open surgery (Lunevicius and Morkevicius 
2005, Bertleff and Lange 2010). However, after laparoscopic operations patients 
experience less pain, and the hospital stay is shorter with a trend toward less 
comorbidity, infections and mortality (Byrge et al. 2013). 
One rare entity is perforation of a marginal ulcer of gastrojejunostomy 
anastomosis located usually on the jejunal site. The incidence of all marginal ulcers 
varies from 1% up to 16% (Chung and Chelat 2017). The incidence of marginal 
ulcers seems to be increasing due to the popularity of Roux-en-Y gastric bypass for 
metabolic syndrome (Altieri et al. 2017, Schulman et al. 2017). The risk of a marginal 
ulcer is significantly higher among patients with the H.pylori infection (OR 11; 6.5-
18) compared to H.pylori negative patients undergoing bariatric surgery (Schulman 
et al. 2017). In a retrospective single-center study from Singapore during 2008-
2012, 2.7% (9/332) of patients operated for PPU had a marginal ulcer (Natarajan 
et al. 2016). Most of them had primary closure or omental patch repair with no 
postoperative complications or need for re-surgery. 
In some PPU cases with spontaneous sealing, conservative management 
including nasogastric suction, intravenous liquids, antibiotics and repeated clinical 
assessment can be used. Patients with conservative management should not be 
hemodynamically unstable, and improvements in daily clinical outcomes should be 
observed during the hospitalisation. According to the previous studies, up to 40-
80% of ulcer perforations will seal spontaneously with conservative management 
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with no significant differences in morbidity and mortality (Chung and Shelat 2017). 
However, the choice of conservative treatment should be based on individual 
evaluation because evidence is scarce (Søreide et al. 2014).     
2.8.5 TRANSARTERIAL ANGIOEMBOLISATION (TAE)
Management by an interventional radiologist in specialised centers is an option 
for surgery in patients with severe and recurrent bleedings who do not respond 
to endoscopic therapy. No prospective randomised studies comparing surgery 
and TAE exist. TAE is associated with higher rebleeding rates with no significant 
difference in mortality when comparing to surgery, but patients admitted to TAE 
were significantly older and might not have been candidates for surgery due to 
comorbidity (Beggs et al. 2014, Kyaw et al. 2014). In a Finnish retrospective study, 
patients admitted to TAE had less postoperative complications, but no difference in 
rebleeding rate or mortality occurred (Nykänen et al. 2017), whereas the utilisation 
of TAE among endoscopy-refractory PUB patients in Denmark was associated with 
a lower 30-day mortality compared to surgical haemostasis (Laursen et al. 2015b). 
In the Netherlands during 2009-2012, 3.8% of all PUB patients were admitted to 
TAE with a significantly higher proportion of patients having a bleeding duodenal 
ulcer (de Groot et al. 2014).
2.9 PROGNOSIS
2.9.1 RECURRENCE
It is essential to confirm that patients with refractory PUD have had appropriate 
standard therapy for PUD and eradication of the H.pylori infection, if needed, 
has occurred. Patient compliance to medication and re-evaluation of possible 
risk factors including underlying illnesses, e.g. Zollinger-Ellison syndrome, is also 
recommended. 
Prior history of PUD was an independent risk factor for asymptomatic PUD in 
the Taiwanese population (OR 2.0; 95%CI:1-3-2.9) (Wang et al. 2011). In addition, 
a history of peptic ulcer was a risk factor for PUB compared to patients suffering 
from non-bleeding peptic ulcers (OR 2.5; 1.4-4.5) (Kang et al. 2011). The risk of 
rebleeding and recurrence is higher among patients with idiopathic ulcers (Wong 
et al. 2009, Chung et al. 2015). 
Peptic ulcers, particularly duodenal ulcers caused by the H.pylori infection, have 
a high rate of ulcer recurrence if the H.pylori infection persists (Gisbert and Pajares 
2003, Yeomans 2011). After H.pylori infection eradication, the annual recurrence 
rate was only 1.9% in Japan (Miwa et al. 2004). In that study, the recurrence rate of 
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gastric ulcers was significantly higher than that of duodenal ulcers. A significantly 
larger proportion of patients with gastric ulcer recurrence were smokers, used 
alcohol and NSAIDs than patients with duodenal ulcer recurrence. The recurrence 
of PUD also occurs significantly more often after duodenal ulcer perforation if the 
H.pylori infection is not eradicated (El-Nakeeb et al. 2009). 
2.9.2 MORTALITY
In a large population-based cohort study, the 30-day standardised mortality rate 
(SMR) was 12 (9.6-14), during the next 11 months 4.0 (3.6-4.4), and during the 
following years up to 10 years 2.5 (2.3-2.7) for patients with uncomplicated PUD, 
and 37 (33-31), 5.1 (4.6-5.6), and 2.6 (2.4-2.8) for complicated PUD (Lassen et al. 
2006). The annual mortality rate from PUD slightly decreased from 7.7 to 6.0 per 
100 000 in the USA during 1992-1999 without statistically significant difference 
(p=0.058) (Lewis et al. 2002). On the contrary, the in-hospital mortality of both 
uncomplicated and complicated PUD patients in the United States between 1993 
and 2006 decreased from 3.8% in 1993 to 2.7% in 2006 (P<0.001) (Wang et al. 
2010). The overall mortality rate for PUD based on death records declined in 
Scotland during 1982-2002 (Kang et al. 2006). At the same time, the in-hospital 
mortality of patients with uncomplicated and complicated gastric ulcers decreased, 
but mortality for duodenal ulcers patients increased. 
The overall mortality associated with PUB has ranged from 5 to 15% (Lau et 
al. 2013, Holster and Kuipers 2012), whereas mortality associated with PPU has 
varied from 1.3% to 30% being higher among elderly patients (Chung and Shelat 
2017). The 30-day overall mortality after emergency surgery for PUD complication, 
perforation or hemorrhage, varied from 4.9% to 10.9% in Finland during 1997-
1999 (Paimela et al. 2004). 
2.9.2.1 Short-term mortality
The short-term mortality usually applies for in-hospital mortality, i.e. case-fatality 
mortality, or 30-day mortality. The case-fatality mortality from PUB was 12% in 
the UK in 1993 (Rockall et al. 1995), including mortality of 2-16% for emergency 
admission patients and 23-38% for in-hospital patients. In more recently published 
studies, mortality from PUB varies between 3-11% (Table 7).  No change in mortality 
from PUB occurred in Denmark (2004-2011) (Rosenstock et al. 2013) or in Sweden 
(1984-2004) (Åhsberg et al. 2010). However, a slight decreasing trend in 28-day 
mortality for PUB patients was observed in England during 1999-2007 (adjusted 
OR 0.96; 0.93-0.99) (Crooks et al. 2011).  
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Table 7. The short-term mortality from peptic ulcer bleeding.
Country In-hospital 
mortality 
rate (%)
30-day 
mortality 
rate (%)
van Leerman 
et al. 2003
The Netherlands 14 --
Lanas et al. 2005 Spain 3.3 (gastric ulcers)
3.5 (duodenal ulcers)
--
Sadic et al. 2009 Sweden -- 3.4
Åhsberg et al. 
2010b* and 2011†
Sweden 5.0* 6.2†
Sung et al. 2010 Hong Kong 5.0 6.2
Nahon et al. 2012 France 5.3 (gastric ulcers)
6.0 (duodenal ulcers)
--
Rosenstock 
et al. 2013
Denmark -- 11
de Groot et al. 2014 the Netherlands 3.8
2.9.2.2 Long-term mortality
Data on long-term mortality associated with PUD is scarce. The long-term survival 
of patients with acute PUB in the United Kingdom in 1991-1995 with a mean 
follow-up of nearly 3 years was significantly reduced compared to the general 
population (Ruigómez et al. 2000). This was seen as well among PUB patients in 
Scotland 1988-1995 (Kubba et al. 1997). In a more recent study from Denmark, the 
long-term mortality with the median follow-up time of 9.7 years was significantly 
higher among PUB patients (Laursen et al. 2015a).
In Germany, the 5-year mortality of patients with PPU treated surgically in 
1986-1995 was 32% (Imhof et al. 2008). The two-year mortality of PPU patients 
in the PULP trial in Denmark varied from 40 to 44% (Møller et al. 2013). The 
long-term (7-year) all-cause mortality in Hong Kong among PUB patients varied 
from 27% in H.pylori-positive up to 57% in H.pylori-negative idiopathic ulcers 
(Wong et al. 2009).
2.9.3 RISK FACTORS FOR MORTALITY
Mortality of PUD patients can be caused by PUD complication or exacerbation 
of comorbidity while hospitalised; hospital resources may also affect outcomes. 
Older age and comorbidities are risk factors for mortality, as well as hemodynamic 
instability on admission (Sung et al. 2010, Åhsberg et al. 2010, Lau et al. 2011, 
Laursen et al. 2015a, Imhof et al. 2008). Among patients with PPU, treatment 
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delay is strongly associated with mortality (Svanes 2000, Mäkelä et al. 2002, Kocer 
et al. 2007 Lau et al. 2011, Søreide et al. 2014, Chung and Shelat 2017). Metabolic 
acidosis, acute renal failure, hypoalbuminemia, smoking, female gender, resection 
surgery and being underweight are also risk factors for mortality among PPU 
patients (Møller et al. 2010, Chung and Shelat 2017).
The stigmata of bleeding among PUB patients did not influence mortality in 
Spain 2006-2009, but the patients with high-risk stigmata suffered more often 
from rebleeding and were referred for surgery (Lanas et al. 2014). On the contrary, 
stigmata of bleeding were associated with the rebleeding rate and mortality in a 
French multicenter study (Nahon et al. 2012). The risk of death was at its highest 
among patients with Forrest Ia (OR 4.1; 1.1-16) and IIb ulcers (5.2; 2.3-12) compared 
to Forrest III ulcers. The risk of rebleeding was 5-19 times higher among patients 
with high stigmata of bleeding, but only 12% of them had had dual treatment for 
high-risk stigmata of bleedings at the index endoscopy. Similarly, major stigmata 
of bleeding were associated with the 30-day mortality in the USA (OR 3.0, 1.3-
7.2) (Camus et al. 2016). In that study, the size of the ulcer was also a risk factor 
for mortality and rebleeding. The risk of mortality was significantly higher among 
patients who started to bleed while hospitalised compared to that of patients 
admitted to hospital due to bleeding symptoms (Loperfido el al. 2009, Åhsberg 
et al. 2010b, Hearnshaw et al. 2011, Camus et al. 2016)
According to a recent systemic review, the risk of death was significantly higher in 
PUB patients with comorbidity than in those without (RR 4.4; 2.5-8.0) (Leontiadis 
et al. 2013). The risk of death was increased by the number of comorbidities. 
Patients with hepatic, renal or malignant disease were at higher risk of death than 
those patients having diabetes, cardiovascular or respiratory disease. In a Danish 
nationwide cohort study on PUB patients, the risk of death within 90 days after 
hospitalisation was significantly higher (2.28; 1.94-2.68) in patients with liver 
cirrhosis compared to those patients without (Holland-Bill et al. 2015). On the 
contrary, no difference in the 30-day mortality was seen in France when comparing 
PUB patients with or without cirrhosis (Rudler et al. 2012). 
The use of ASA decreased the risk of death in a Swedish study cohort of PUB 
patients (OR 0.12; 0.01-0.67), whereas the use of bleeding promoting drugs did 
not affect mortality (Åhsberg et al. 2010). Therefore, the use of low-dose ASA as 
a secondary prophylaxis for cardiovascular diseases is recommended to resume 
soon after hemostasis to prevent mortality from thromboembolic events (Laine 
and Jensen 2012, Lau et al. 2013). The use of corticosteroids increased the risk 
of mortality among PUB patients in Denmark (RR 2.88; 1.78-4.67) (Laursen et 
al. 2015). The increased level of mortality among corticosteroid users was also 
observed among PPU patients (Christensen et al. 2006). 
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2.9.4 CAUSES OF DEATH
In a large prospective cohort study from Hong Kong, the majority (80%) of PUB 
patients deceased within 30 days died of non-bleeding related causes of death (Sung 
et al. 2010). Terminal malignancy was the most common cause of death in 34% 
of the deceased patients followed by multiorgan failure and pulmonary disease. 
Of the patients who died of bleeding related complications, 30% had uncontrolled 
bleeding or rebleeding, one fourth died within 48h after endoscopy without any 
other cause indicating failure of hemostasis, and 30% died for surgical complication 
or within 1 month after surgery. The reported causes of death in the PUB patient 
cohort in Denmark were as follows: 34% cardiovascular, 16% malignancy, 10% 
infection and 1.3% PUB with no difference in the main causes of death compared 
to the age- and gender-matched controls; except 0nly 0.3% of controls died of 
PUB (P=0.047) (Laursen et al. 2015). 
In a retrospective register-based Swedish study during 1987-2007, the risk of 
acute myocardial infarction or stroke was significantly higher among patients with 
no previous history of cardiovascular diseases after hospitalisation for PUD than 
that for the general population (Sadr-Azodi et al. 2011). In a French cohort including 
all upper gastrointestinal bleeding patients (one third of PUB patients), 29% died 
of bleeding-related causes, 18% of hepatic failure, 13% of sepsis/infection and 
11% of cardio-respiratory failure (Nahon et al. 2012). These observations indicate 
that mortality associated with PUD is more often explained rather by comorbidity 
than the PUD disease or its complication, but both have an effect on the patient´s 
outcome. 
In a retrospective study of PPU patients from Turkey during 2001-2004, the 
30-day mortality was 8.5%, and main causes of death were as follows: myocardial 
failure 39%, sepsis 38%, pneumonia/acute respiratory distress syndrome 17%, and 
renal failure 4% (Kocer et al. 2007). Of all the patients deceased, 87% were over 
65 years old. The mortality rate after PPU surgery in Northern Finland during 
1979-2000 was 14% with abdominal sepsis being the most common cause of death 
followed by cardiovascular events (Mäkelä et al. 2002).
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3 AIMS OF THE STUDY
The main aims of this thesis were to evaluate:
I
The time trends of incidence rates of PUD and its complications in hospitalised 
patients during 2000-2008
II
PUD associated mortality and causes of death
III
Risk factors for PUD mortality
IV
Significance of PUD among hospitalised patients admitted for acute OEGD  
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4 PATIENTS AND METHODS
4.1 IDENTIFICATION OF PATIENTS (I-IV)
The retrospective register study (I and II) was conducted as an epidemiological 
cohort study during 2000 to 2008. The data came from the Helsinki and Uusimaa 
Hospital register containing all hospital admissions and discharge diagnoses from 
the whole district. Adult (≥18 years) patients, hospitalised and diagnosed with 
PUD, were identified from the register in the capital region of Finland, within a 
catchment area of 1.2 million people. Only patients living permanently in the capital 
region were included. Data retrieval was based on the International Classification 
of Diseases, 10th edition (ICD-10) codes for PUD (Table 8).
The number of diagnoses settled for each hospitalisation can vary from one to 
five, with the first one being the primary diagnose and the possible following ones 
secondary diagnoses. In our study, the retrieval code could have been any of five 
possible diagnoses of a patient during hospitalisation, with the majority (85%) 
of patients having PUD as their primary diagnosis.  Cases were regarded in this 
manner, as we assumed that some may have been overlooked if we included only 
those with PUD listed as their primary diagnosis. All hospitalisations regardless of 
the duration of stay were included. Those patients hospitalised due to PUD within 
3 months before the study period started were excluded. The recurrent PUD case 
was considered when there were more than three months between the first and 
the successive hospitalisation for PUD during the study period for neither to miss 
real new ulcer cases nor to analyse old cases based on the hospital register. 
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Table 8. The International Classification of Diseases, 10th edition, codes for data retrieval of patients 
hospitalised with PUD.
K25 
Gastric 
ulcer
K25.0 Acute with haemorrhage
K25.1 Acute with perforation
K25.2 Acute with both haemorrhage and perforation
K25.3 Acute without haemorrhage or perforation
K25.4 Chronic or unspecified with haemorrhage
K25.5 Chronic or unspecified with perforation
K25.6 Chronic or unspecified with both haemorrhage and perforation
K25.7 Chronic without haemorrhage or perforation
K25.9 Unspecified as acute or chronic, without haemorrhage or  
perforation
K26 
Duodenal 
ulcer
K26.0 Acute with haemorrhage
K26.1 Acute with perforation
K26.2 Acute with both haemorrhage and perforation
K26.3 Acute without haemorrhage or perforation
K26.4 Chronic or unspecified with haemorrhage
K26.5 Chronic or unspecified with perforation
K26.6 Chronic or unspecified with both haemorrhage and perforation
K26.7 Chronic without haemorrhage or perforation
K26.9 Unspecified as acute or chronic, without haemorrhage or  
perforation
K27 
Peptic 
ulcer, site 
unspecific
K27.0 Acute with haemorrhage
K27.1 Acute with perforation
K27.2 Acute with both haemorrhage and perforation
K27.3 Acute without haemorrhage or perforation
K27.4 Chronic or unspecified with haemorrhage
K27.5 Chronic or unspecified with perforation
K27.6 Chronic or unspecified with both haemorrhage and perforation
K27.7 Chronic without haemorrhage or perforation
K27.9 Unspecified as acute or chronic, without haemorrhage or perfo-
ration
K28 
Gastro-
jejunal 
ulcer
K28.0 Acute with haemorrhage
K28.1 Acute with perforation
K28.2 Acute with both haemorrhage and perforation
K28.3 Acute without haemorrhage or perforation
K28.4 Chronic or unspecified with haemorrhage
K28.5 Chronic or unspecified with perforation
K28.6 Chronic or unspecified with both haemorrhage and perforation
K28.7 Chronic without haemorrhage or perforation
K28.9 Unspecified as acute or chronic, without haemorrhage or  
perforation
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For the prospective observational study (III and IV), all consecutive adult patients 
(N=1580 cases) admitted for acute upper endoscopy (oesophagogastroduodenoscopy 
=OEGD) were recruited in two hospitals (Meilahti and Jorvi hospitals) in the 
capital area of Finland during two years (from March 2012 to April 2014). The 
definition of acute upper endoscopy was the need for acute OEGD during the 
hospitalisation based on clinical decision (e.g. hematemesis, melena, acute anaemia, 
severe dysphagia). The exclusion criteria were 1) patients unable to provide written 
informed consent (e.g. due to severe dementia, language problems) (N=145 cases), 
2) refusal to participate in the study (76), 3) patients who were out-of-citizens (183), 
4) patients who were not reached (e.g. due to day case endoscopies, inappropriate 
information from the endoscopy unit to the research nurses) (392), 5) No common 
language for including to the study (22). Re-endoscopy was regarded as an 
endoscopy made within one month of the previous one due to the same indication.
4.2 DEFINITION OF INCIDENCE (I)
The annual incidence rates per 100 000 at-risk adults (≥18 years) were calculated 
by dividing the number of new PUD cases requiring hospitalisation by the total 
number of population during each calendar year between 2000 and 2008. The 
same patient could have been a new PUD case if hospitalised for PUD after three 
months since the previous hospitalisation. For the time trend analysis, the study 
cohort was divided into three subcohorts by three time periods (2000-2002, 2003-
2005, and 2006-2008).  The cumulative incidence of recurrence of PUD requiring 
hospitalisation was expressed as percentage and calculated by dividing the number 
diagnosed recurrence cases by all ulcers at risk. 
The population sizes for calculation of incidence rates came from the Official 
Statistics of Finland. During the study period, the adult population of the capital 
region of Finland increased 9% (from 1 085 597 to 1 184 360 inhabitants), which 
was taken into consideration in statistical calculations. At the end of 2008, the 
entire Finnish population totalled 5.33 million.
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4.3 NATIONAL CAUSE OF DEATH REGISTER (II) AND    
 MORTALITY (II-IV)
The retrospective data was linked with Statistics Finland’s national cause of death 
data by unique personal identity codes assigned to every Finn. Mortality and main 
causes of death were recorded by the end of 2009.
The long-term prognosis of PUD patients (II) was compared to that of the 
background population (relative survival ratio) matched with regard to age, gender, 
and calendar period.
For the survival analysis of patients in the prospective study part (III-IV), 
patients were followed until 31st October 2015. Mortality and possible causes of 
deaths were available in hospital patient charts.
4.4 PRESCREPTION/DRUG PURCHASE REGISTER OF THE   
 FINNISH SOCIAL INSURANCE INSTITUTION (I-II)
Data on patients hospitalised with PUD was linked with the nationwide Drug 
Purchase Register of the Finnish Social Insurance Institution (SII) to provide 
detailed information on prescribed and reimbursed medical product purchases 
of each individual patient. Over-the-counter (OTC) purchases are not registered 
in the SII system. 
4.5 DATA COLLECTION FOR THE PROSPECTIVE STUDY  
 PART (III-IV)
In addition to data obtained from the hospital patient charts (including endoscopy 
reports and laboratory tests), the study nurses personally interviewed the patients 
who were recruited with a written informed consent. Data on lifestyle habits 
(current smoking, alcohol use), weight and height to calculate body mass index 
(=BMI), use of medications including over-the-counter products, and symptoms 
prior the endoscopy was collected. Alcohol abuse was determined by using the 
Alcohol Use Disorders Identification Test (Reinert and Allen 2002).
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4.6 STATISTICAL ANALYSIS
The descriptive statistics include the means and standard deviations (SDs) for 
continuous variables and numbers and percentages for categorical variables. 
The statistical significance of differences in baseline characteristics was assessed 
using the t-test for continuous variables and the chi-square or Fisher´s exact test 
for categorical variables (I-III). In addition, the permutation test and Fisher-
Freeman-Halton test were used in statistical comparison between the groups when 
appropriate (IV). The normality of variables was evaluated by the Shapiro-Wilk 
W test (IV).
All the statistical analyses for incidences were first made for all cases, and then 
related to gender, age groups, and the three time periods (2000-2002, 2003-2005, 
and 2006-2008) (I). The 95% confidence intervals (95% CI) for the incidence rates 
per 100 000 were calculated assuming a Poisson distribution. The standardised 
estimates of rate ratios (RR) for drug purchases between the PUD patients and the 
age- and gender-adjusted general population were calculated by using Poisson or 
negative binomial regression models when appropriate. The cumulative incidence 
function (CIF) (95%CI) was used to describe of recurrent ulcers with Grays´s test. 
Fine and Gray competing risks proportional hazards models was used to calculate 
the age- and gender-adjusted hazard (sHR) for different drugs (I-II).
The Kaplan-Meier estimation served to illustrate information on the cumulative 
proportions of survival (II-III). The Cox proportional hazard model served to 
estimate the adjusted risk for death between the PUD patient groups (II), and the 
multivariable model was used to determine the independent effect of multiple risk 
factors on the hazard for risk of death among PUD patients (III). The proportionality 
assumption was tested using Schoenfeld residuals, and it was found to be satisfied 
by this test. In analysing obesity as a risk factor for death, we also assessed non-
linear trends of risk using restricted cubic-spline Cox regression with three knots 
(10, 50 and 90 percentiles) of the Body Mass Index (III).
The ratio of observed to expected number of deaths, the Standardised Mortality 
Ratio (SMR) for all-cause deaths, was calculated using subject-years methods with 
95% CIs, assuming a Poisson distribution (II). SMR is expressed as either a ratio 
of percentage quantifying the increase or decrease in mortality. Probabilities of 
survival in an age- and gender-matched sample of the general population were 
calculated from data of the Official Statistics of Finland. The relative survival was 
calculated as the ratio of the observed survival rate of PUD patients to the expected 
survival rate in the population matched with regard to age, gender, and calendar-
period by the Ederer II method (Ederer and Heise 1959).
All statistical analyses were performed with Stata (versions 12.0/1 or 14.0/1) 
(StataCorp, Collage Station, TX, USA). Statistician Hannu Kautiainen was involved 
in the study design and statistical analysis.
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4.7 ETHICAL CONSIDERATIONS
Ethical approval for the retrospective, register-based study was unnecessary, and 
no informed consent was required in accordance with the Finnish regulations 
for register-based studies. We used only encrypted register data and did not 
contact the always-unidentifiable study subjects. However, the study protocol 
of the retrospective part of the thesis was accepted by the coordinating ethical 
committee of Helsinki University Hospital (404/13/03/00/2009). The study 
protocol of the prospective part of the thesis was also accepted by the coordinating 
ethical committee of Helsinki University Hospital (HUS310/13/03/01/11). Written 
informed consent was obligatory for gaining access to the patient data.
48
5 RESULTS
5.1 PATIENT CHARACTERISTICS (I-IV)
In the retrospective register-based study part (I and II), a total of 9951 peptic ulcer 
cases leading to hospitalisation were diagnosed among 8146 individual patients 
(4330 men and 3816 women). The mean (±SD) age of adults at the time of PUD 
diagnosis was 60 (±14) years for men and 66 (±15) years for women, respectively 
(p < 0.001). 
In the prospective study part (III and IV), 762 out of 1580 acute upper 
endoscopies performed during the study period were included with written 
informed consent. Of all endoscopy cases, 85% (N=649 individual patients) were 
primary endoscopies. The mean age of adult patients at the time of primary 
endoscopy was 61 (±16) years. Of them 57% were men. 
The number of patients with PUD diagnosed in acute OEGD was 147 (III). The 
mean age of all PUD patients was 66 (±15) and 57% of them were men. The mean 
age of patients with GI bleeding symptoms but negative OEGD was 66 (±16) and 
47% were men (IV).
5.2 INCIDENCE OF PUD AND ITS COMPLICATIONS IN 
HOSPITALISED PATIENTS AND RECURRENCE (I)
During the whole study period, the crude mean annual incidence of hospitalised 
PUD was 97 per 100 000. During 2000-2008, divided into three time intervals, 
the crude mean annual incidence of all peptic ulcer cases decreased from 121 per 
100 000 (95% CI: 117-125), to 79 (76-82) in 2006-2008 [the periodic incidence 
rate ratio (IRR) = 0.62 (0.58-0.64), p<0.001 after adjusting for age and gender]. 
The number of cases with diagnosis for uncomplicated and complicated peptic 
ulcers with unspecified site (ICD-10 code group K27) or gastrojejunal ulcers (K28) 
was low (N=541) during the whole study years, and thus they were not analysed as 
subgroups. The annual incidence of PUD was significantly higher in men than in 
women (p<0.001, after adjusting for age) during the all three time intervals. The 
annual incidence of PUD increased by age (Figure 6). The incidences of both gastric 
and duodenal ulcers decreased in both genders (Table 9), as well as incidences of 
complications (Table 10). However, the decrease in incidence of complications was 
mainly due to a decrease in PUB cases. Of all PUD cases, 49% had a complication. 
The incidence of complications increased markedly by age. 
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Table 9. Mean annual incidence rates (IR) per 100 000 of peptic ulcers during the three periods of 
2000-08 in Finland according to gender and anatomical location.
2000-2002
IR (95%CI)
2003-2005
IR (95%CI)
2006-2008
IR (95%CI)
Women
  GU
  DU
  Total
  71 (67-75)
  31 (28-34)
102 (97-107)
57 (53-60)
24 (22-27)
81 (77-85)
46 (43-50)
20 (18-22)
66 (62-70)
Men
  GU
  DU
  Total
  78 (73-82)
  51 (48-55)
129 (123-135)
 62 (58-66)
 42 (38-45)
103 (98-108)
55 (52-59)
28 (25-30)
83 (79-87)
All
  GU
  DU
  Total
 74 (71-77)
 40 (38-43)
115 (111-118)
59 (56-62)
32 (30-34)
91 (88-95)
51 (48-53)
23 (22-25)
74 (71-77)
GU=gastric ulcer; DU=duodenal ulcer
The cumulative incidence of recurrent ulcers during the first year after the 
primary ulcer was 13.1% (95% CI: 12.4-13.9). Use of several different drugs elevated 
the risk for recurrent ulcer compared to PUD patients with no use of drugs one year 
before the first ulcer (p for linearity = 0.014 after age and gender adjusted). The use 
of corticosteroids for systemic use, PPIs, coxibs, and blood glucose lowering drugs 
excluding insulins elevated the risk for PUD recurrence in univariate analysis, but 
the use of hormone antagonists and related agents was associated with a decreased 
risk (Table 11). In multivariate analysis, only the use of PPIs was associated with 
an increased risk of PUD recurrence (sHR=1.08; 95%CI: 1.05-1.11, p<0.001 after 
age and gender adjustment). Differences in purchases of various drug groups one 
year before the diagnosis of peptic ulcer were observed between the PUD patients 
and the age- and gender-matched background population, generally PUD patients 
had more often purchased different drugs indicating comorbidity (Table 4 in the 
original paper I).
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Table 10. Mean annual incidence rates (IR) per 100 000 of severe PUD complications during the three 
periods 2000-08 in Finland according to gender and anatomical location.
2000-2002
IR (95%CI)
2003-2005
IR (95%CI)
2006-2008
IR (95%CI)
Total 53 (51-56) 49 (47-51) 37 (35-39)
Gastric ulcer
  Total
    Women
      Hemorrhage
      Perforation
      Hemorrhage and perforation
    Men
      Hemorrhage
      Perforation
      Hemorrhage and perforation
36 (34-38)
22 (20-25)
9 (7-11)
5 (4-6)
30 (27-33)
7 (5-8)
5 (4-6)
32 (30-34)
21 (19-24)
4 (3-5)
5 (3-6)
26 (24-29)
7 (6-8)
2 (2-3)
24(23-26)
13 (12-15)
6 (5-7)
1 (0-1)
21 (19-23)
7 (6-8)
2 (1-3)
Duodenal ulcer
  Total
    Women
      Hemorrhage
      Perforation
      Hemorrhage and perforation
    Men
      Hemorrhage
      Perforation
      Hemorrhage and perforation
17 (16-19)
8 (7-10)
4 (3-5)
<1 (<1-1)
19 (17-22)
3 (2-4)
2 (1-3)
17 (16-19)
9 (8-11)
3 (2-4)
1 (<1-2)
18 (16-20)
5 (4-6)
1 (<1-2)
12 (11-13)
7 (5-8)
3 (2-4)
<1 (<1-1)
11 (9-13)
3 (2-4)
1 (<1-2)
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The cumulative incidence of recurrent ulcers during the first year after the 
primary ulcer was 13.1% (95% CI: 12.4-13.9). Use of several different drugs 
elevated the risk for recurrent ulcer compared to PUD patients with no use of 
drugs one year before the first ulcer (p for linearity = 0.014 after age and 
gender adjusted). The use of corticosteroids for systemic use, PPIs, coxibs, 
and blood glucose lowering drugs excluding insulins elevated the risk for 
PUD recurrence in univariate analysis, but the use of hormone antagonists 
and related agents was associated with a decreased risk (Table 11). In 
multivariate analysis, only the use of PPIs was associated with an increased 
risk of PUD recurrence (sHR=1.08; 95%CI: 1.05-1.11, p<0.001 after age and 
Figure 6. Age and gender specific annual incidence of peptic ulcer disease with 95% confidence intervals 
during 2000-2008 in Finland.
Table 11. Drug groups purchased one year before the first ulcer with significant impact on the risk of 
peptic ulcer recurrence in univariate analysis.
Drug group (ATC code) sHR* p
Corticosteroids for systemic use (H02A) 1.31 (1.07 to 1.59) 0.008
Proton pump inhibitors (A02BC) 1.30 (1.15 to 1.47) <0.001
Coxibs (M01AH) 1.23 (1.01 to 1.50) 0.039
Blood glucose lowering drugs,  
excluding insulins (A10B)
1.23 (1.01 to 1.49) 0.037
Hormone antagonists and related  
agents (L02B)
0.13 (0.02 to 0.90) 0.039
* Age and gender adjusted hazard risk (Fine and Gray competing risks 
proportional hazards model)
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5.3 PUD ASSOCIATED MORTALITY AND CAUSES OF DEATH (II)
The mortality of PUD patients was based on a mean follow-up time of 4.9 years. 
The number of deaths observed among PUD patients during 2000-2008 was 
2 798 with SMR being 2.53 (95% CI: 2.44-2.63). SMR varied from 1.79 to 2.92 
regarding the ulcer site and complication among the PUD patients (Table 12). No 
statistically significant change in the one-year SMR occurred between the three 
time periods during 2000-2008 (Figure 7).
Table 12. Standardised mortality ratio (SMR) in the study´s peptic ulcer population during 2000-2008 
by ulcer site and complication.
Number 
of cases
Number 
of person 
years
Observed 
numbers 
of death
SMR
Gastric
  Uncomplicated
  Bleeding/Perforated
5 008
2 411
2 597
24 039
12 437
11 603
1 842
   756
1 086
2.59 (2.47-2.71)
2.23 (2.08-2.39)
2.92 (2.75-3.10)
Duodenal
  Uncomplicated
  Bleeding/Perforated
2 675
1 332
1 343
13 936
  7 635
  6 300
  816
  339
  477
2.45 (2.29-2.63)
1.97 (1.77-2.19)
2.97 (2.72-3.25)
Other
  Uncomplicated
  Bleeding/Perforated
  463
  429
   34
2 225
2 073
  152
  140
  126
    14
2.30 (1.95-2.72)
2.38 (2.00-2.83)
1.79 (1.06-3.01)
ALL
  Uncomplicated
  Bleeding/Perforated
8 146
4 172
3 974
40 200
22 145
18 055
2 798
1 221
1 577
2.53 (2.44-2.63)
2.16 (2.05-2.29)
2.92 (2.78-3.07)
0 2 4 6
2000-02
2003-05
2006-08
Men
Women
SMR
Figure 7.  The one-year standardised mortality ratios (SMRs) with 95% CIs in three-year study periods 
by gender. 
53
Patients with uncomplicated PUD survived significantly better than patients 
with complicated disease (p<0.001). The overall long-term survival of patients 
with gastric ulcer was worse than that of patients with duodenal or other subgroup 
(gastrojejunal or unspecific site ulcers) ulcers (p=0.030).  The short-term survival 
of patients with PPU was worse than that of bleeding or uncomplicated ulcer 
patients; at six months the risk of death (hazard ratio) was 2.06 (adjusted for 
age, gender and ulcer site) (95% CI: 1.68-2.54) for perforated and 1.32 (95% CI: 
1.11-1.58) for bleeding ulcers compared to the patients with uncomplicated PUD. 
On the long run, survival of patients with bleeding ulcers turned out to be worse 
than that of PPU patients.
Of all PUD patients in the cohort study, 300 (3.7%) died within 30 days and 958 
(11.8%) within one year. PUD was regarded as a main cause of death in one third 
of patients who died within 30 days (Figure 8).  For one-year mortality, the relative 
ratio of PUD as a main cause of death was only less than 15% (Figure 9). Malignancies 
turned out to be the main cause of mortality followed by cardiovascular diseases. 
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Main causes of death ≤30 days
Cardiovascular Malignancy Other GI PUD
Figure 8. Main causes (%) of death within 30 days according to three study periods.
The short- and long-term survival of perforated duodenal ulcer patients 
differed between genders, survivals were significantly worse among women (Table 
13). Survival at one year among women with perforated gastric ulcer was also 
significantly impaired compared to men. When comparing the overall survival of 
PUD patients to the survival of the age- and gender-adjusted general population, 
the relative survival of PUD patients worsened continuously during the whole 
follow-up of nine years (Figure 4 in the original paper II).
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Figure 9. Main causes (%) of death within one year according to three study periods.
The previous (one year before the ulcer) purchases of different drugs and risk 
of mortality were analysed among the survived and deceased PUD patients. The 
risk of one-year death was increased among patients using oral corticosteroids 
and diuretics, whereas the use of lipid modifying agents, practically statins, did 
decrease the risk of death (Table 14). The use of PPI, H2-receptor antagonist, or 
combinations for eradication of H.pylori was not associated with the one-year risk 
of death in the univariate age- and gender-adjusted analysis. No difference in the 
survival of patients using different pain killers occurred, nearly without exceptions. 
The previous purchase of oxicams decreased the risk of death in patients with 
complicated gastric ulcers. 
The use of lipid modifying agents before the index hospitalisation for PUD was 
associated with a decreased risk of 5-year mortality in all PUD patients (Table 15). 
The use of oral corticosteroids, diuretics and antidepressants including SSRIs was 
associated with a worse long-term survival. The use of PPIs was associated with 
a decreased risk of 5-year mortality among patients with complicated duodenal 
ulcers (HR0.72; 0.56-0.93).  
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Table 13.  
30
-day, 1-year, and 5-year survival rates (%
) of peptic ulcer study patients by gender.
U
lcer site
30
-d
ay su
rvival (9
5%
 C
I)
1-year su
rvival (9
5%
 C
I)
5-year su
rvival (9
5%
 C
I)
W
om
en
M
en
W
om
en
M
en
W
om
en
M
en
G
astric
  U
ncom
plicated
  B
leeding
  Perforated
96.3 (95.4-96.9)
98.5 (97.7-99.0)
95.6 (94.0-96.8)
90.6 (87.0-93.2)
96.4 (95.6-97.1)
98.2 (97.2-98.8)
96.0 (94.7-97.1)
94.0 (91.2-96.0)
87.5 (86.1-88.7)
91.0 (89.4-92.5)
86.7 (84.2-88.8)
76.9 (72.1-81.0)
88.2 (86.8-89.4)
90.6 (88.7-92.2)
86.8 (84.5-88.7)
86.5 (82.7-89.6)
68.8 (66.8-70.7)
75.3 (72.7-77.6)
61.4 (57.8-64.7)
63.8 (58.2-68.8)
67.5 (65.4-69.4)
71.4 (68.4-74.2)
62.5 (59.2-65.6)
70.5 (65.4-75.1)
D
uodenal
  U
ncom
plicated
  B
leeding
  Perforated
95.0 (93.5-96.2)
99.0 (97.7-99.5)
94.4 (91.4-96.3)
83.0 (75.9-88.2)
97.1 (96.2-97.8)
99.1 (98.1-99.6)
96.2 (94.4-97.4)
93.1 (88.4-95.9)
86.3 (84.1-88.2)
91.9 (89.3-93.8)
83.1 (78.7-86.6)
74.2 (66.3-80.5)
90.5 (88.9-91.8)
93.9 (91.9-95.4)
87.7 (84.9-90.0)
86.7 (81.0-90.8)
71.3 (68.3-74.0)
78.5 (74.7-81.8)
67.1 (61.6-71.9)
54.2 (45.2-62.3)
75.6 (73.3-77.7)
79.7 (76.5-82.5)
70.5 (66.7-74.1)
77.1 (70.1-82.6)
O
ther      
  U
ncom
plicated
  C
om
plicated
97.7 (94.6-99.1)
97.7 (94.3-99.0)
100 
95.9 (92.5-97.8)
95.5 (91.8-97.5)
100
91.8 (87.3-94.8)
92.8 (88.3-95.6)
75.0 (40.8-91.2)
87.6 (82.8-91.2)
87.3 (82.2-91.2)
90.9 (68.3-97.7)
74.1 (67.0-79.9)
75.0 (67.6-80.9)
58.3 (27.0-80.1)
71.9 (65.4-77.4)
72.9 (66.1-78.5)
64.1 (38.5-81.2)
A
LL
 U
ncom
plicated
 C
om
plicated
96.0 (95.3-96.3)
98.5 (97.9-99.0)
92.9 (91.5-94.0)
96.6 (96.1-97.1)
98.2 (97.5-98.7)
95.2 (94.3-96.0)
87.4 (86.3-88.4)
91.4 (90.2-92.6)
82.4 (80.5-84.1)
89.0 (88.0-89.9)
91.4 (90.1-92.6)
86.7 (85.3-88.1)
69.8 (68.2-71.3)
76.2 (74.2-78.0)
62.0 (59.5-64.4)
70.7 (69.3-72.1)
74.6 (72.6-76.6)
67.2 (65.1-69.2)
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Table 14. The purchase/use of different drugs in multivariate forward stepwise Hazard regression (HR) models 
with 95% confidence intervals (95% CI) for one-year risk of death from any cause.
Gastric ulcers Duodenal ulcers
Drug group (ATC 
code)
Uncomplicated 
HR (95% CI)*
Complicated
HR (95% CI)*
Uncomplicated 
HR (95% CI)*
Complicated
HR (95% CI)*
Insulins and 
analogues (A10A)
3.20 (1.46-7.00)
Antithrombotic 
agents (B01A)
1.43 (1.00-2.03) 2.05 (1.19-3.55)
Diuretics (C03) 2.00 (1.50-2.67) 1.50 (1.21-1.87) 1.69 (1.03-2.74) 1.84 (1.36-
2.48)
Lipid modifying 
agents plain 
(C10A)
0.63 (0.22-0.91) 0.70 (0.51-0.94) 0.16 (0.06-0.45) 0.50 (0.31-
0.80)
Corticosteroids 
for systemic use 
(H02A)
1.84 (1.27-2.66) 2.30 (1.69-3.13) 2.45 (1.57-
3.83)
Thyroid 
preparations 
(H03A) 
0.44 (0.22-0.60) 0.46 (0.21-
0.98)
Oxicams (M01AC) 0.39 (0.20-0.75)
*Forward selection. Only those variables shown that entered the age- and  
gender-adjusted model. 
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Table 15. The purchase/use of drugs in multivariate forward stepwise Hazard regression (HR) models with 95% 
confidence intervals (95% CI) for 5-year risk of death from any cause.
Gastric ulcers Duodenal ulcers
Drug group 
(ATC code)
Uncomplicated 
HR (95% CI)*
Complicated
HR (95% CI)*
Uncomplicated 
HR (95% CI)*
Complicated
HR (95% CI)*
Drugs for PUD 
and GORD
(A02B except for 
A02BC) 
0.62 (0.42-0.92)
Proton pump 
inhibitors 
(A02BC)
0.72 (0.56-0.93)
Insulins and 
analogues (A10A)
2.53 (1.52-4.21) 2.23 (1.45-3.43)
Antithrombotic 
agents (B01A)
1.55 (1.09-2.19)
Cardiac glycosides 
(C01A)
1.30 (1.03-1.65)
Diuretics (C03) 1.92 (1.61-2.29) 1.47 (1.26-1.71) 1.83 (1.36-2.46) 1.67 (1.33-2.08)
Lipid modifying 
agents plain 
(C10A)
0.64 (0.51-0.80) 0.76 (0.63-0.92) 0.47 (0.31-0.70) 0.50 (0.35-
0.69)
Corticosteroids 
for systemic use 
(H02A)
1.61 (1.26-2.06) 1.79 (1.42-2.26) 2.03 (1.39-2.96)
Acetic acid 
derivatives and 
related (M01AB) 
substances
1.38 (1.01-1.88)
Other analgesics 
and antipyretics, 
incl. acetylsalicylic 
acid (N02B)
1.42 (1.05-1.91)
Antidepressants 
(N06A)
1.42 (1.15-1.74) 1.53 (1.29-1.81) 1.42 (1.00-2.01)
*Forward selection. Only those variables shown that entered  
the age- and gender-adjusted model.
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5.4 MORTALITY AND ASSOCIATED RISK FACTORS OF PATIENTS  
 HOSPITALISED WITH PUD DIAGNOSED IN ACUTE OEGD (III)
Of all acute upper endoscopies performed during 2012-2014, 762 out of 1580 
(48.2%) were included into the study analysis. Of all endoscopy cases included, 
85.2% (N=649 individual patients) were primary endoscopies, and 14.8% (113) 
were re-endoscopies. PUD was the most common diagnosis occurring in 147 (23%) 
individual patients with melena being the leading symptom for OEGD indication. 
Of all PUD patients, 35% had major stigmata of bleeding (Forrest Ia-IIb) at 
the time of endoscopy. No statistically significant differences in gender, age, BMI, 
smoking, drinking habits, comorbidity (Charlson comorbidity index), or drug use 
occurred between patients with minor or major stigmata of bleeding. Patients 
with major bleeding stigmata were treated with dual therapy using epinephrine 
injections and fibrin glue in 83%, clips in 4%, and both fibrin glue and clips in 6%, 
whereas 8% of patients had no endoscopic therapy. 
The 30-day mortality was 0.7% (95%CI: 0.01-4.7). None of the PUD patients 
died during hospitalisation. The one-year mortality was 12.9% (8.4-19.5) and 
the two-year mortality 19.4% (13.8-26.8). No statistically significant difference 
in mortality appeared between the patients categorised into the low- and high-
risk Forrest classes [HR=1.45 (0.54 to 3.89), p=0.45, post-hoc power 59%]; after 
adjusted for age, gender, and Charlson class HR=1.25 (0.57 to 2.74), p=0.57). 
The risk of death was increased among patients with ≥2 comorbidities (Table 16). 
Underweight did not affect the risk of death, but obesity (BMI≥30) was associated 
with a significantly decreased risk of death. 
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Table 16. Univariate hazard ratios (HR) with 95% confidence intervals (95% CI) for risk of death among 
peptic ulcer patients.
Risk factor HR (95% CI) P-value
Men 1.18 (0.54 to 2.61) 0.67
Age per 10 years 1.26 (0.91 to 1.75) 0.16
Charlson class 0.029*
   0 1 (reference)
   1  1.56 (0.52 to 4.72)
   ≥2 2.93 (1.10 to 7.83)
Body mass index 0.90 (0.82 to 0.99) 0.025
Smoking 0.55 (0.22 to 1.38) 0.21
AUDIT 0.80*
  <8 1 (reference)
  8-19 0.52 (0.15 to 1.89) 
   ≥20 1.18 (0.33 to 4.17)
Forrest IIc-III 1.45 (0.54 to 3.89) 0.45
Timing of OEGD, days 0.43*
   0 1 (reference)
   1 0.62 (0.27 to 1.42)
   2-3 0.90 (0.30 to 2.69)
Number of re-endoscopies 0.45*
   0 1 (reference)
   1 0.83 (0.22 to 3.09)
   ≥2 2.29 (0.70 to 7.52)
*p for linearity
AUDIT=Alcohol Use Disorders Identification Test
OEGD=Oesophagogastroduodenoscopy
5.5 OUTCOMES OF PATIENTS WITH ACUTE BLEEDING   
 SYMPTOMS BUT NEGATIVE OEGD (IV)
Of all primary upper endoscopies during 2012-2014, in 121 out of 649 (19%) 
patients no cause for symptoms of acute GIB was diagnosed. PUD was the most 
common (23%) diagnosis among patients referred for acute upper endoscopy. 
The distribution of other specific diagnoses was as follows: oesophagitis (12%), 
oesophageal or gastric varices (10%), gastroduodenitis (10%), Mallory-Weiss lesion 
(8%), and malignancy (5%).
Most patients with no findings in OEDG (87%) had melena or haematochezia as 
an indication for endoscopy. These patients were divided into three subgroups based 
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on comorbidity: no comorbidity, one comorbidity, or serious/several comorbidities. 
Patients with more comorbidity (Charlson class ≥2) were older (mean age 74 years, 
SD ±11) than the patients with no comorbidity (54 ±17) (p<0.001). No difference 
in BMI, smoking or alcohol consumption occurred regarding comorbidity. Of all 
patients, 60% used at least one bleeding-related drug regardless of comorbidity. 
Patients with comorbidity (≥1 comorbidity) used bleeding-related drugs more 
often than the patients with no comorbidity (p=0.012). The further examinations 
undertaken were based on clinical decisions (Table 17). The distribution of findings 
in further examinations is showed in Table 18. None of the patients (N=121) died 
within 30 days. The one-year mortality was 5.8% (95CI%: 2.4 -11.6).
Table 17. The further examinations undertaken among patients with a negative OEGD.
102 Colonoscopies (89 after negative OEGD, 13 recently 0-2 years prior) 
With other examinations 
     20 CT-angiographies
     13 Capsule endoscopies
       3 Virtual CT colonoscopies
       2 Double-balloon enteroscopies
       2 Surgical operations
2 Re-OEGD
1 Proctoscopy
5 Refused for colonoscopy
1 Died before scheduled elective colonoscopy
1 Colonoscopy referral not done for unknown reason
3 Colonoscopy referral to occupational health care or another department 
6 No further examinations on clinical judgment
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Table 18. Findings in further examinations that most probably explain previous acute gastrointestinal 
bleeding symptoms among patients with negative OEGD by Charlson class.
Charlson=0
N=42 (%)
Charlson=1
N=39 (%)
Charlson≥2
N=40 (%)
P-value
Diverticular disease of 
colon
10 (24) 20 (51) 17 (43) 0.033
No possible source of
bleeding identified
14 (33) 7 (18) 8 (20) 0.23
Colonic angioectasia 4 (10) 1 (3) 3 (7) 0.50
Cancer 1 (2) 1 (3) 3 (7) 0.53
Adverse effect of drug 
therapy
1 (2) 1 (3) 2 (5) 0.84
Hemorrhoids 2 (5) 0 (0) 2 (5) 0.54
Other 8 (19) 3 (8) 3 (7) 0.21
Data not available 2 (5) 6 (15) 2 (5) …
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6 DISCUSSION
6.1 ACUTE GASTROINTESTINAL BLEEDING
One fourth of the patients referred for OEDG for acute GIB symptoms had a peptic 
ulcer in our study cohort during 2012-2014 (III) being the most common source of 
bleeding as seen in many other studies (Vreeburg et al. 1997, Leerdam et. al 2003, 
Loperfido et al. 2009, Nahon et al. 2012, Miilunpohja et al. 2017). Acute GIB is a 
universal medical emergency leading to hospitalisation including both upper and 
lower GIBs. Acute upper GIB originates from anywhere proximal to the Ligament 
of Treiz, whereas bleedings from other sources of the GI tract are traditionally and 
in most studies defined as lower GIB. After introduction of capsule endoscopy 
and double-balloon endoscopy, the definition of middle gastrointestinal bleeding 
occurring between the papilla Vateri and ileocecal valve in the small bowel has 
been proposed (Ell and May 2006, Raju et al. 2007).
The incidence of acute upper GIB is decreasing according to the published data 
(van Leerdam et al. 2003, Lanas et al. 2009, Loperfido et al. 2009) being 45-160 per 
100 000 inhabitants per year (Vreeburg et al. 1997, Paspatis et al. 2000, Åhsberg 
et al. 2010a, Button et al. 2011). On the other hand, the incidence of acute lower 
GIB seems to be increasing (Lanas et al. 2009, Lanas et al. 2011) varying from 21 
to 87 per 100 000 inhabitants per year in previous studies with the highest level 
reported from Iceland in 2010 (Longstreth 1997, Hreinsson et al. 2013). However, 
contradictory results have been reported from the USA during 2001-2009, where 
the incidence of both acute and lower GIB decreased by 15-23% during the study 
years (Laine et al. 2012). 
The incidence of PUB decreased in Finland during 2000-2008 (I) as reported in 
other studies (Wang et al. 2010, Åhsberg et al. 2010b, Lanas et al. 2011, Laine et al. 
2012). However, the incidence of PUB varying 9-87 per 100 000 is still remarkable 
comparing to that of reported incidences of all acute lower GIB (Bardhan et al. 
2004, Pérez-Aisa et al. 2005, Lassen et al. 2006, Åhsberg et al. 2010). In addition, 
most lower GIBs stop spontaneously. One possible explanation for a downward 
trend in PUB is the decreasing prevalence of the H.pylori infection in Finland and 
other Western countries (Kosunen et al. 1997, Pérez-Aisa et al. 2005). However, one 
third of PUB patients tested positive for the H.pylori infection in our prospective 
study cohort during 2012-2014 (III).  
The impact of newer anticoagulants introduced during the last ten years on 
the incidence of acute GIBs is not settled. According to a recent meta-analysis, 
the risk of major GIB with NOACs is, after initial concerns, at the same level as 
with the older vitamin K antagonists (Caldeira et al. 2015). As seen in Sweden 
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during 1984-2004, patients with acute upper and lower GIBs in the beginning of 
the 21st century were older, had more comorbidity and more often used bleeding 
related drugs (Åhsberg et al. 2010a). Older age and comorbidity are independent 
risk factors for morbidity and mortality associated with both upper and lower 
GIBs (Strate et al. 2008, Åhsberg et al. 2010a, Crooks et al. 2013). Therefore, the 
incidence of acute GIB might again increase in the future.
6.2 INCIDENCE OF PUD AND ITS COMPLICATIONS
The incidence of PUD and its complications leading to hospitalisation decreased 
significantly from 121 to 79 per 100 000 during 2000-2008 in Finland (I). The 
decrease in the incidence was seen in all age groups and in both genders. The 
incidence of PUD was higher among men and increased by age as shown in other 
previous studies (Pérez-Aisa et al. 2005, Kang et al. 2006, Lassen et al. 2006, 
Post et al. 2006, Cai et al. 2009, Feinstein et al. 2010). The incidence of both 
uncomplicated and complicated PUD cases decreased. That is partly contrary to 
the Danish results, where the incidence of uncomplicated PUD and PPU decreased, 
but that of bleeding ulcers remained stable during 1993-2002 (Lassen et al. 2006). 
In our retrospective study, the mean annual incidence rate of both uncomplicated 
and complicated PUD hospitalisation was 97 per 100 000, being in line with other 
studies reporting that incidence varies from 55 to 165 per 100 000 (Lewis et al. 
2002, Pérez-Aisa et al. 2005, Feinstein et al. 2010, Åhsberg et al. 2011). 
Previously, the incidence of hospital admission for complicated PUD was 
analysed in Finland 1972-1999 with a 79% increase in admissions (Paimela 
et al. 2002). In that previous Finnish study, the increase in complicated PUD 
hospitalisation was mainly due to bleeding gastric ulcers in elderly women. A 
significant decrease in the incidence of bleeding ulcers was seen in our cohort, 
except the incidence of duodenal ulcer bleeding remained stable among women 
(I). However, a decreasing trend of all PUB cases as seen in our study has also been 
shown in other countries (Wang et al. 2010, Åhsberg et al. 2010b, Lanas et al. 2011).
The decreasing trend in all PUD complications was mainly due to a decrease 
in all bleeding ulcers during 2000-2008. The incidence of PPU remained stable 
during the study years, being 6-7 per 100 000 for gastric ulcer perforations in 
2006-2008 and 3 per 100 000 for duodenal ulcer perforations (I). As well, no 
change in the annual operation rate for PPU was seen in the Northern Finland 
during 1979-2000 (Mäkelä et al. 2002). On the other hand, based on data from the 
National Research and Development Centre for Welfare and Health, operations for 
PPU increased significantly in the whole Finland during 1987-1995, but remained 
stable during the years 1996-2000 (Paimela et al. 2004). Our results are in line 
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with the reported incidence of PPU varying from 4 to 14 per 100 000 (Pérez-Aisa 
et al. 2005, Åhsberg et al. 2011, Lau et al. 2011).
The proportion of gastric-ulcer patients was nearly twofold than that of 
duodenal-ulcer patients in the retrospective study cohort (I). This might be a 
consequence of the decreasing incidence of the H.pylori infection, whereas gastric 
mucosa is more vulnerable to NSAIDs. The prevalence between duodenal and 
gastric ulcers has varied in previous studies, the majority of them having more 
duodenal ulcers especially in studies with PUB patients (Pérez-Aisa et al. 2005, 
Lanas et al. 2006, Bardhan and Royston 2008, Sadic et al. 2009, Sung et al. 
2010, Rosenstock et al. 2013). In our prospective cohort of bleeding ulcers, the 
proportion of gastric ulcers was slightly higher than that of duodenal ulcers (III). 
Similar results have been reported from Sweden, where hospitalisation rates for 
gastric ulcer bleeding were higher than for duodenal ulcer bleeding during 1987-
2005 (Åhsberg et al. 2011) and as well as from the Netherlands during 2009-2012 
(de Groot et al. 2014). The incidence of uncomplicated gastric ulcer in Denmark 
was also slightly higher than that of uncomplicated duodenal ulcers (Lassen et 
al. 2006). In that study, the distribution of complicated ulcers was not reported, 
but the proportion of possible NSAID-induced ulcers increased significantly from 
being 39% in 1993 to 53% in 2002 (p<0.01).
The cumulative one-year recurrence (≥3 months after the index hospitalisation) 
rate was 13% in our study cohort (I). The use of multiple drugs significantly increased 
the risk of recurrence. In a USA-based study, a significant increase in polypharmacy 
among adults is seen during the last 10 years, being at its highest among adults 
65 years or older (Kantor et al. 2015). In our study, patients with recurrent PUD 
were neither analysed separately by initial site and complication of PUD nor by 
manifestation of a recurrent ulcer. In a large Danish population-based cohort study, 
33% of PUB patients had a recurrent complication within 3 months and 14% of 
PPU patients (Lassen et al. 2006). In the long run (median follow-up varied from 
2.7-3.7 years), 9% of PUB patients had a recurrent complication compared to 7% 
of PPU patients in that study. During the follow-up (median of 4.0 years) starting 
after three months after the initial hospitalisation with their first uncomplicated 
PUD, 3% of patients experienced PUD complication. The recurrence rate after 
PUB has varied between 0-38% with regard to the  definition of recurrence time 
being on average 10% and that after PPU varying from 0.4% to 25%, with 12% 
being average. Very small numbers of recurrence have been reported in studies 
including H.pylori positive ulcer patients with successful eradication therapy after 
the initial hospitalisation (Miwa et al. 2004, Gisbert et al. 2012). After an ulcer 
episode, risk factors such as H.pylori infection and inappropriate use of NSAIDs 
are possible to eliminate, whereas the effect of increasing age and comorbidities as 
risk factors for recurrence, morbidity and mortality are not. The use of PPI before 
hospitalisation for PUD was associated with an increased risk of PUD recurrence 
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in our study cohort (I), suggesting that the patients at high-risk for ulcer formation 
are recognised.
6.3 MORTALITY ASSOCIATED WITH PUD
The short-term 30-day mortality associated with PUD was 3.7% in the retrospective 
cohort study (II) and 0.7% in the prospective study (III). The difference in the short-
term mortality is most probably explained by the exclusion of unstable patients 
at the admission in the prospective cohort study. Hemodynamic instability at 
admission is an independent risk factor for mortality (Lau et al. 2011). Patients 
who were unable to give written informed consent due to severe dementia, e.g., 
were also excluded in the latter cohort (III); that might have led to exclusion 
of older patients with comorbidities affecting mortality. In the prospective study 
cohort 92% of patients with high-risk stigmata of ulcer bleeding had endoscopic 
dual therapy compared to only 12% in a French cohort with a higher in-hospital 
mortality of 5.8% (Nahon et al. 2012) or 38% in the UK audit cohort with mortality 
of 8.9% (Hearnshaw et al. 2010). Besides good adherence to the recommended 
dual therapy for high-risk ulcers in our study cohort, none of the patients needed 
surgery or TAE. These factors also explain the low short-term mortality rate in 
our cohort.
The mean 30-day mortality associated with PUD hospitalisation in Finland 
during 1995-1999 based on death certificates of patients who died of PUD or its 
surgery was 3.7% (Paimela et al. 2004). The 30-day mortality in our retrospective 
study cohort (II) was at the same level, but only one third of mortality that occurred 
within 30 days was explained by PUD as a main cause of death. So presumably, the 
all-cause mortality associated with PUD has decreased from the 1990s, although 
no decrease occurred during 2000-2008.
The in-hospital mortality for all PUD patients in the USA was 2.7% in 2006 
(Wang et al. 2010). In that USA-based study, 86% of patients experienced a 
complicated peptic ulcer compared to 49% in our study cohort (I). The 30-day 
mortality was not analysed in the USA, but one might expect it to be at about 
same level as seen in our study. The 30-day mortality for uncomplicated PUD in 
Denmark 1993-2002 was 2.6% and for complicated PUD 11%. Most studies have 
reported mortality from complicated PUD. The short-term mortality (in-hospital 
or 30-day) associated with PUB has varied from 3.4% to 14% (van Leerdam et al. 
2003, Lanas et al. 2005, Sadic et al. 2009, Åhsberg et al. 2010b and 2011, Sung et 
al. 2010, Nahon et al. 2012, Rosenstock et al. 2013). The all-cause 30-day mortality 
among PUB patients in our study varied from 3.8% to 5.6% in the retrospective 
study, being at the same level as in other countries. 
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The short-term mortality after PPU was about 10% in our study cohort varying 
from 6% among gastric ulcer perforations in men to 17% among duodenal ulcer 
perforations in women. Patients with PPU were not analysed regarding to operative 
or conservative treatment after PPU diagnosis. The short-term mortality after PPU 
surgery has varied from 7.5% (Paimela et al. 2004) to 14% (Mäkelä et al. 2002) in 
previous reports from Finland. According to a recent literature review, mortality 
associated with PPU varies from 1.3% to 30% (Chung and Shelat 2017).
However, no difference in one-year mortality emerged between the PUD patients 
in the retrospective (11.8%) and prospective (12.9%) study cohorts (II and III). 
According to other studies, excess mortality among PUD patients in the long run 
is explained by comorbidity (Wong et al. 2009, Holland-Bill et al. 2015, Laursen et 
al. 2015a, Liang et al. 2016). Malignancies and cardiovascular diseases explained 
over 50% of deaths that occurred during the first year after PUD hospitalisation 
in our study. The impaired survival among the patients once hospitalised for PUD 
compared to the age-and gender-adjusted population was also shown to worsen 
continuously during the follow-up time. Therefore, hospitalisation for PUD might 
be considered as a warning sign with a demand for an evaluation of individual 
patient´s overall health status. 
Interestingly, patients on statin therapy before the first ulcer had a better 
short- and long-term survival in our cohort. The most probable explanation for 
our finding of reduced short- and long-term mortality in PUD patients on statins 
is their effect on overall mortality, which was demonstrated in a recent large meta-
analysis showing a significant reduction in all-cause mortality among patients 
with statin therapy (Cholesterol Treatment Trialists’ (CTT) Collaboration 2015). 
Furthermore, among elderly people with no known history of vascular events, the 
use of statins or fibrates was also associated with a 30% decrease in the incidence 
of stroke (Alpérovitch et al. 2015). On the other hand, in a Taiwanese population-
based cohort study, the risk of developing PUD was significantly lower among the 
statin users, suggesting that statins might act as potential gastroprotective agents 
by inhibiting neutrophil activity, reducing oxidative stress and maintaining vascular 
integrity (Feng et al. 2015). 
6.4 RISK FACTORS FOR PUD ASSOCIATED MORTALITY
Comorbidity was associated with a significant increase in the risk of death in the 
prospective study (III), as well as the use of oral corticosteroids and diuretics, 
indicating cardiovascular comorbidities among PUD patients in the retrospective 
study cohort (II). In addition, most patients died of non-PUD-related causes in 
the retrospective study cohort as seen in other studies, indicating the impact of 
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comorbidity in survival of hospitalised PUD patients (Imhof et al. 2008, Sung et 
al. 2010, Åhsberg et al. 2010, Lau et al. 2011, Laursen et al. 2015a). 
In our prospective cohort, increasing age was not associated with mortality, 
probably due to the exclusion of some patients (III). The annual incidence rate 
of PUD increased by age during the retrospective study years 2000-2008 (I). 
The association between increasing age and mortality in PUD patients is shown, 
however, in many other studies (Soplepmann et al. 1997, van Leerdam et al. 2003, 
Imhof et al. 2008, Sung et al. 2010, Åhsberg et al. 2010, Laursen et al. 2015a).
Obesity was shown to decrease the risk of mortality among PUB patients 
compared to normal or underweight patients (III). Obesity, in the population 
level, is associated with morbidity and mortality (Masters et al. 2013). However, 
the “obesity paradox” meaning better survival has been reported to occur among 
patients admitted to intensive care units, for an emergency abdominal operation 
or hospitalised for cardiac failure or ischemic stroke (Casas-Vara et al. 2012, Kim 
et al. 2012, Pickkers et al. 2013, Benjamin et al. 2017). On the other hand, obese 
trauma patients had more complications and worse survival that the normal weight 
patients in a large USA-based retrospective cohort study (Glance et al. 2014). In 
a Danish study on patients with PPU, obesity did not affect survival, whereas 
underweight was associated with poorer survival after surgery (Buck and Møller 
2014). The pathophysiology of obesity with decreased risk of mortality among 
hospitalised patients is unclear. One explanation could be that obese patients are 
in good nutritional status compared to those patients with normal BMI but already 
suffering poorer nutritional stage caused by severe comorbidity.
The timing of endoscopy did not have an effect on survival in our prospective 
cohort study (III). Our result is similar to that seen in Denmark, where the timing 
of endoscopy was not associated with mortality in stable PUB patients with an ASA 
score of 1-2 (Laursen et al. 2017b). However, in our prospective PUB cohort, patients 
with more comorbidity were also included if they were hemodynamically stable 
enough to give the written informed consent. In the Danish study, patients who were 
unstable at admission or were both unstable and had more comorbidity (ASA 3-5) 
had better survival if they experienced an upper endoscopy 6-24 (unstable patients) 
or 12-36 (unstable patients with comorbidity) hours after admission, indicating the 
importance of resuscitation and managing comorbidities (Laursen et al. 2017b). 
This was also stated in the international recommendations for performing early 
endoscopy within 24 hours with no additional benefit from more urgent procedures 
(Barkun et al. 2010, Gralnek et al. 2015). However, patients who are already at 
hemodynamic shock at the time of admission have a worse survival (Lau et al. 
2011). Results of the studies on the “weekend effect” (patients who are hospitalised 
out of office hours) on mortality are controversial, but no such effect was shown 
to occur in the most recent prospective international study (Murray et al. 2017). 
The “weekend effect” was not analysed in our study cohorts.
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The rebleeding rate before the modern era of endoscopic therapies was high, 
being up to 55% after PUB with major stigmata of hemorrhage with mortality of 
11% (Laine and Petersen 1994). The major stigmata of bleeding are considered 
as a risk factor for mortality (Lau et al. 2011, Camus et al. 2016). However, no 
difference in mortality between the high- and low-risk stigmata patients in Spain 
2006-2009 was observed (Lanas et al. 2014). That is in line with results from 
our prospective study 2012-2014 (III), suggesting the good quality of endoscopic 
therapy. Similarly shown in the Netherlands 2009-2012, no correlation between 
Forrest classification and mortality occurred (de Groot et al. 2014). Patients who 
start to bleed while hospitalised for another cause are at increased risk of mortality 
compared to patients admitted to hospital for bleeding-related symptoms (Åhberg et 
al. 2010b, Hearnshaw et al. 2011, Camus et al. 2016). The proportion of in-hospital 
bleeders was not known in our study cohorts.
Among PPU patients, a delay in surgery of more than 24 hours after admission 
is associated with a significantly poorer outcome (Svanes 2000, Mäkelä et al. 2002, 
Kocer et al. 2007 Lau et al. 2011, Søreide et al. 2014, Chung and Shelat 2017). 
In our retrospective register-based study with no access to patient charts, it was 
not possible to analyse if a delay in surgery or decision to treat a PPU patient 
conservatively affected the survival of PPU patients (II). These factors besides 
comorbidity might explain the significantly worse survival among women with 
perforated duodenal ulcers compared to that of men. 
6.5 OUTCOMES OF PATIENTS WITH ACUTE BLEEDING   
 SYMPTOMS BUT NEGATIVE OEGD
The proportion of patients with acute bleeding symptoms referred for OEDG but 
no diagnosed source of bleeding in the upper GI tract was 19% in the prospective 
study cohort (IV). In other studies, the reported proportion of patients with no 
diagnosis has varied from 5% to 28% with no explanation of underlying cause for 
bleeding symptoms (Vreeburg et al. 1997, van Leerdam et al. 2003, Lanas et al. 
2005, Lanas et al. 2009, Loperfido et al. 2009, Hearnshaw et al. 2011, Nahon et 
al. 2012, Miilunpohja et al. 2017). The reported in-hospital mortality has varied 
between 6-16%, which is clearly at a higher level than in our study. This difference 
is most probably explained by the exclusion of the most vulnerable and unstable 
patients. 
The diverticular disease of the colon was regarded as the most probable source 
of bleeding in one third of patients (IV). That is also seen in studies on lower GI 
bleedings, explaining approximately one third of bleedings (Longstreth 1997, Gayer 
et al. 2009, Hreinsson et al. 2013). The diverticular disease of the colon as a bleeding 
source was more common in patients with comorbidities in our study cohort; these 
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patients also used more often bleeding-related drugs. The use of NSAIDs, ASA or 
calcium channel blockers was associated with diverticular bleedings according to 
a recent systematic review (Kvasnoysky et al. 2014). 
As being an observational cohort study, further examinations were undertaken 
by clinical decision during the hospitalisation (IV). Therefore, the source of bleeding 
remained unknown for 24% patients. The proportion of those patients could 
have been smaller if all possible further examination methods including, e.g., 
capsule enteroscopy or double-balloon enteroscopy were utilised during the index 
hospitalisation. On the other hand, the proportion of patients with no diagnosis has 
varied from 3-12% in lower GI tract studies (Longstreth 1997, Gayer et al. 2009, 
Hreinsson et al. 2013). Besides, the costs of all the possible further examinations 
and hospitalisation days would have been remarkable when considering the very 
low mortality of this cohort. 
Mortality among these patients was very low: none of the patients deceased 
within 30 days, and seven (5.8%) died within a year mainly due to chronic diseases 
(alcoholic cirrhosis, lung cancer, aortic stenosis, Alzheimer´s disease) (IV). 
Therefore, a clinical decision not to utilise all the available examination methods 
seems to be reasonable. In addition, further examinations after OEGD can be 
undertaken as elective procedures in most patients without lengthening the initial 
hospital stay. As seen in a study from the USA, urgent colonoscopy identified better 
the definite bleeding source among patients with acute lower GIB (OR 2.6; 95%CI 
1.1-6.2), but without differences in outcomes (Green et al. 2005).  
6.6 STRENGTHS AND LIMITATIONS OF THE STUDY
In the retrospective register-based study part (I and II), data on hospitalised 
PUD patients only might reduce the number of false-positive cases compared 
to studies reporting physician-diagnosed PUD in primary care. A recent analysis 
of 32 different studies comparing The Finnish Hospital Discharge Register 
data to external information showed that more than 95% of discharges could 
be identified from the register (Sund 2012). Positive predictive value (PPV) for 
common diagnoses ranged between 75-99%, suggesting that the completeness and 
accuracy in the register seem to vary from satisfactory to very good. In addition, 
based on systematic review of study methods, our study design most probably 
underestimates the incidence for uncomplicated PUD (Lin et al. 2011).
The retrospective study part also has some limitations. The study was conducted 
as a retrospective epidemiological study based on hospital records of patients 
requiring hospitalisation for their PUD and on hospitalised patients who have 
had their ulcer disease diagnosed during the hospital visit. Our epidemiological 
study describes trends and associations with PUD, but can´t define causation 
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of the disease. The major limitation of the study was unavailability of data on 
comorbidities and living habits. Besides, the H.pylori status and changes in drug 
therapy after the ulcer were not known. Therefore, the relative risks of drug therapy 
affecting survival after hospitalisation may not be clinically relevant in the long run.
The prospective study part (III and IV) was conducted as an observational cohort 
study, where all the included patients had upper endoscopy and were individually 
interviewed by a trained study nurse. In addition, access to the hospital records 
was available in order to obtain all information on risk factors for the short- and 
long-term mortality. For the patients with negative OEGD (IV), results of previous 
and further examination could be evaluated for the analysis.
However, written informed consent was mandatory, leading to a quite 
high number of patients excluded from the analysis.  That might have led to 
underestimation of mortality and to patient selection bias when interpreting the 
study results. Among PUD patients (III) no statistically significant difference in 
mortality appeared between the patients categorised into the low- and high-risk 
Forrest classes, but the result of post-hoc power calculation was 59% suggesting 
that in a larger cohort a difference could possibly have emerged. Although PUD was 
the most common diagnosis in the primary endoscopy, the number of individual 
patients with PUD was only 147. The number of individual patients without 
diagnosis at the primary endoscopy was 121 (IV). As being an observational study, 
no possibilities to interfere with clinical judgments on patient care were allowed 
by the study group.
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7 CONCLUSIONS
I
The incidence of PUD and its complications requiring hospitalisation decreased 
significantly in the capital area of Finland during 2000-2008. The one-year 
recurrence rate of PUD was quite high at 13%, although the recurrence was defined 
when the first and the successive hospitalisation occurred after more than three 
months to exclude hospitalisation for ulcer healing controls. The PUD patients 
used drugs more often than the age- and gender-adjusted background population, 
suggesting more comorbidity. The use of several drugs increased the risk of 
recurrence. The use of PPI was also associated with a slight increase in recurrence. 
II
During the study period 2000-2008 no difference in SMR occurred among the 
patients hospitalised for PUD. The short-term 30-day mortality associated with 
PUD was 3.7%, and the long-term one-year mortality was 11.8%. The short- and 
long-term survival of women with a perforated duodenal ulcer was significantly 
impaired compared to that of men. The overall survival compared to the age- and 
gender-matched background population was worse among PUD patients, and it 
decreased constantly up to a follow-up of nine years. PUD explained one third of 
mortality occurring within 30 days. PUD was considered as a main cause death 
only in less than 15% deaths occurring within one year, whereas malignancies and 
cardiovascular were the main causes of death in over 50% of cases. The previous 
use of statins was associated with a significant decrease in all-cause mortality 
among all PUD patients.
III
PUD is still the most common source of bleeding in hospitalised patients referred for 
acute OEDG during 2012-2014. The short-term mortality among PUD patients was 
low 0.7%, but 12.9% of patients died within one year. Comorbidity was associated 
with an increase risk of death, whereas obesity (BMI>30) was associated with 
better survival. However, age, gender, smoking or drinking habits, stigmata of 
ulcer haemorrhage (low- or high-risk stigmata), timing of endoscopy or number 
of re-endoscopies did not affect on survival. 
IV
Of all patients admitted for acute OEGD during hospitalisation in 2012-2014, 
no reason for bleeding symptoms was diagnosed in 19% of patients. In further 
examinations, the diverticular disease of the colon was regarded as the most 
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probable source of previous bleeding symptoms in one third of patients. Further 
examinations were undertaken by clinical decision; therefore, the source of bleeding 
remained unidentified in 24% of these patients. No patient died within 30 days, 
and the one-year mortality was 5.8%.  
Further perspectives
Although the incidence of PUD is decreasing, the management of patients 
presenting with complicated PUD is becoming more challenging. The results of 
medical and interventional treatments for peptic ulcers are good. The utilisation 
of angioembolisation in fragile PUB patients, possibly unfit for surgery, is 
emerging. However, mortality associated with PUD among the elderly population is 
remarkable. Therefore, recognising PUD before its complication occurs is essential, 
as well as the management of a patient´s comorbidity while hospitalised for PUD. 
The growing antimicrobial resistance to H.pylori eradication therapy, as seen in 
other Western countries, is also worrying and can lead to a plateau or even an 
increase in PUD occurrence. Patients starting long-lasting NSAID therapy should 
be tested for the H.pylori infection. In addition, patient adherence to GPAs should 
be evaluated in patients with an increased risk of PUD. 
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